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Probing Protein Interactions with Stapled Peptides: 
Myc Family and Insulin Receptor 
 
Abstract 
 One of the most exciting frontiers of expanding pharmacopeia to combat 
currently untreatable diseases is achieving specifically and potently disruption of 
unwanted protein-protein interactions where traditional small molecule drugs tend 
to fall short. Our laboratory has developed the methodology of peptide stapling and 
pioneered successful applications in multiple disease models since its induction 
over a decade ago. One common feature of past applications is the use of a single 
stapled peptide in helical form, derived from the natural binding interface of target 
proteins. This dissertation ventures into protein interactions that involve multiple 
components and sites and explores the extended use of stapled peptides in these 
volatile settings.  
Up-regulation of the proto-oncogene Myc, a transcription factor in the 
Myc/Mad/Max network, is linked to abnormal growth and evasion of apoptosis in many 
types of cancers. Transcriptional activation by Myc roots in three major interactions: 
heterodimerization with Max, binding to DNA, and recruitment of histone modifying 
proteins. Max, the functional opposite of Myc, undergoes similar dimerization and DNA 
binding but solicits repression machinery that leads to gene silencing. The three distinct 
interactions – dimerization, DNA binding, and recruitment of transcriptional 
activators/repressors – are achieved by structural domains that have been shown to be 
portable by protein engineering and chimeric studies. We designed and synthesized 
iv 
 
artificial transcriptional factors by fusing a stapled repression domain to a recombinant 
DNA-binding and dimerization domain via different methods. The physical properties of the 
fusion proteins have kept us from testing their potential in biochemical assays or in vivo 
models; nonetheless, we have gained experience with the molecules that may aid future 
efforts on improving their properties. 
The insulin receptor (IR) ectodomain crystal structure shows the C-terminal domain 
of the α-subunit (α-CT) lying across the central α-sheet of L1 domain, indicating its critical 
role in insulin binding.  Previously, surrogate peptides have been evolved by phage display 
to bind to one of the two insulin-binding sites on IR.  Among these hits is S371, a 
prototypical site 1 peptide with sequence similarity to α-CT of IR, possibly a mimetic.  We 
synthesized a comprehensive library of stapled peptides based on S371 including all 
possible locations of hydrocarbon crosslink along the sequence. Screening of the library for 
IR and Akt1 phosphorylation has identified several potent antagonists of IR signaling, with 
IC50 at about 1 µM.  All hits feature non-natural amino acid substitutions on fixed “hot 
spots” on the S371 sequence that render the crosslink on just one face of the helix, 
presumably to preserve the binding interface.  Biochemical assays were performed to 
support the structural model of S371 occupying the same binding site as αCT. We expect 
further optimization of the stapled peptide hits to achieve higher potency and agonistic 
effects, and aim for solving the structure of receptor: peptide complex that will help unravel 
mechanisms of receptor activation.  
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Chapter I –Stapled Peptides and Proteins for Targeting the Myc 
Network 
 
Introduction 
At the core of the modern approach for drugging a disease lie two doctrines of practice: 
first, find the genes and proteins whose aberrant behavior is the cause of the disease; 
second, find a way to either correct for or remove such behavior, frequently in the form of a 
chemical compound physically binding to the target and rendering it inactive.  Though 
many breakthroughs in drug discovery have been made possible by efforts following these 
guidelines, the current situation is at its most challenging of all time on both regards.  
For one thing, finding the right target(s) is hard. Long gone was the naïve belief that any 
disease could be pinned to one (or even just a defined number of) molecular deregulation(s) 
as its cause. The handful of single gene disorders are likely more of an exception than a rule, 
and have been better off used as poster-child stories to fill up introductory genetics or drug 
design text books that lure future generation of researchers or physicians. Most diseases 
that still elude effective treatment today have been found over long periods of research to 
implicate tens or hundreds of genes and proteins with no set pattern but large individual 
variation.  Even in the rare and marvelous event when targeting of a single enzyme is 
sufficient to overcome disease state, such as the famous case of imatinib and its target BCR-
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ABL in chronic myeloid leukemia (CML), resistance arises when the specific drug-protein 
interaction is compromised by mutations as seen in many CML patients under treatment og 
imatinib1. Indeed, the more knowledge we gain, the clearer it drives home that the 
battlefront of identifying and targeting the intricate molecular networks that cause diseases 
is mercurial and ever expanding. 
For another, chemists strive to expand the reservoir of compounds and synthetic 
methodologies to yield potential therapeutics, but find it harder and harder to keep up with 
the growing complexity of biological tasks at hand. Most drugs in the pharmacopoeia today 
work in the same way – they bind to defined clefts in target proteins to shut them off 
functionally. Not surprisingly the list of targets druggable by such means also consists of 
similarly structured proteins; for example, more than a quarter are of the class of G-protein-
coupled receptors (GPCR), which in turn represent less than 2% of the entire human 
genome2. Granted, the conventional way of drug discovery – screening of tens of thousands 
of small molecules for the ability of inhibiting a particular protein – has received 
tremendous success in presenting us with almost all of the drugs that became available in 
the last century, more than all previous ones combined. It turns out, however, that there are 
only so many low-hanging fruits available for picking, so to speak. As mentioned above, 
disease biology is increasingly found to involve complex processes such as multi-
component interactions, crosstalk between proteins, DNA, and regulatory RNA, and global-
level events that change cell fate altogether. Turning a single molecule off simply would not 
suffice, but beyond this realm screening of a traditional small molecule library does not 
have much to offer. Modulation of multifaceted networks and events requires a matching 
increase in sophistication and dimensionality of chemicals and methods in the toolbox. 
Facing this demand, chemists have stepped up to meet the challenge, developing new 
paradigms of synthetic strategy to yield structurally diverse and complex molecules in a 
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high throughput and scalable manner3. Much progress has been made on targeting 
undruggable interactions by screening new generations of libraries. In addition to small 
molecules, “big molecules”, i. e. biologics have entered the arena. These are peptides, 
monoclonal antibodies, nucleic acids, etc. derived from relevant biological context and thus 
inherently better poised at targeting said context. But formulation and delivery of these 
more volatile molecules pose new problems unfamiliar to conventional medicinal 
chemistry. Nonetheless, biologics often exhibit insurmountable specificity and potency if 
their pharmacologic properties are optimized, and represent a new hope and foundation for 
the development of next-generation therapeutics. 
Albeit daunting for the reasons discussed above and more, research in both doctrines 
continues to evolve and thrive. Revolutionary studies hit major periodicals every so 
frequently, and there has never before been a more exciting time to be part of the 
broadening community of disease-oriented biologists and chemists alike. The theme of this 
dissertation is precisely methodology and compound development with the aim of studying 
and potentially drugging perhaps some of the most invincible of all diseases: cancer and 
diabetes. Incidentally, our approach is one inspired by both small molecules and biologics: 
chemically-modified peptides.  
The idea of stabilization of peptides in the α-helical structure through chemical modification 
is not new. Demand for methodologies that enable short peptides to retain their native α-
helical conformation even when taken apart from their parent protein is ever growing, 
especially as helices account for much of the known protein-protein interfaces. Approaches 
in the past include cross-linking of side chains, hydrogen bond surrogate (HBS) helices, β-
peptides and other peptidomimetics4-7. Although these methods yielded stabilized peptides 
or mimetics that demonstrated increased helical character in vitro, their use as probes or 
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potential therapeutics in disease biology has been scarce due to a variety of limitations, 
such as susceptibility to disruption or degradation in the physiological chemistry 
environment, loss of binding affinity to protein partners, low cell penetration level, etc. 
Our laboratory has developed another way to “lock” peptides in their helical conformation 
via incorporation of non-natural amino acids: peptide stapling8. All-hydrocarbon cross-
linking of a peptide via metathesis of olefin-containing unnatural amino acids, a technique 
developed in our lab, enables solid phase peptide synthesis (SPPS) of α-helices that exhibit 
enhanced helicity, cell-permeability, and metabolic stability. Significantly, stapled peptides 
have been shown to be exceptionally specific and highly potent to unwanted protein-
protein interactions in multiple disease models both in vitro and in vivo9-13. Recent progress 
in our lab indicates that they may even transport various types of cargo attached to them 
into cells. Equipped with this powerful toolkit, we would like to undertake a fresh approach 
in tackling an omnipresent yet extremely elusive target in cancer biology: the 
Myc/Mad/Max transcriptional network.   
 
The Myc/Mad/Max Transcription Factor Family 
Proteins Myc and Mad belong to a family of eukaryotic transcriptional factors (TF) that 
possess the basic helix-loop-helix/leucine zipper (bHLH-LZ) motif. The domain organization 
of major members is shown in figure 1.1. Both of the proteins form heterodimers with Max, 
another bHLH-LZ TF, via interaction between the LZ domains. When dimerized, the bHLH 
domains of Myc and Mad recognize the same DNA sequence known as the E-Box14-16. 
Despite the numerous common features they share, Myc and Mad usually trigger opposite 
effects in gene expression. Simply put, Myc tends to activate transcription by association of 
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its N-terminus with TRRAP, a member of the HAT complex SAGA. Conversely, the N-
terminus of Mad recruits Sin3, part of an HDAC complex, thus resulting in gene silencing17-19. 
Despite the direct involvement 
of its constitutive activity in 
many types of cancer, Myc has 
received far less attention as a 
potential drug target than it 
deserves. Firstly, many of Myc’s 
target genes are essential for 
cell growth and maintenance. 
Secondly, disruption of protein-
protein interactions is in 
general hard to achieve by small molecule drugs. Recent studies, however, have shown that 
a dominant interfering mutant, termed “Omomyc”, inhibits lung tumor growth in mice, with 
tolerable and reversible effects on other regenerating tissues20,21. Encouraged by the 
therapeutic potentials of Myc, the propose study seeks to answer the other side of the 
question – whether Myc can be inhibited by methods not involving exogenous gene delivery.  
 
Design of Stapled Repression Domains and Semi-synthetic Transcription Factors 
Reviewing of successful applications of the stapled peptide strategy for targeting disease-
causing, deregulated protein interactions (mostly oncogenic proteins) in the past shows a 
common feature of design: all stapled peptides developed for a host of different targets are 
based on sequences from the respective natural interaction partner; they form part of the 
binding interface that researchers were trying to disrupt. In this way, they could be 
 
Figure 1.1.  Domain organization of Myc family 
members.  BR, basic region; HLH, helix-loop-helix domain; 
Zip, leucine zipper; TAD, transcriptional activation domain; 
SID, Sin3-interaction domain.  Omomyc is derived from Myc 
by N- and C-terminal truncation down to the core bHLH-Zip 
domain, plus introduction of the four denoted amino acid 
substitutions. 
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classified as dominant negatives that occupy the same site on the target protein as the 
“parent” molecule from which they are derived, blocking its access. By virtue of dramatic 
increases in binding affinity, stability, and bio-availability from installation of hydrocarbon 
staples, these dominant negatives become great competitive inhibitors that work in the 
same type of logic as small molecule drugs of the classical “bump-hole” strategy, except the 
“bump” and “hole” in question are much larger and flatter surfaces. While there is no doubt 
that this approach has the advantage of simplicity and can work well in certain systems, it is 
by far not a universal solution. Not all protein-protein interactions are as simple as the form 
of a single helix on one protein engrossed by a cleft on another. Many include more than site 
of interaction constituted by more than two components, as is the case of Myc/Max, 
Mad/Max dimers and their binding to DNA we discussed earlier.  
Our lab had put considerable efforts on targeting the Myc/Max transcriptional machinery 
via a similar design of developing stapled peptides as dominant negatives. At first glance, 
the heterodimer of Myc and Max bound to DNA, although elaborate in structure and 
interaction motifs, still seemed quite amenable to the old approach. In theory, a peptide 
need not touch all of the interaction sites to disrupt formation of the complex – one is likely 
enough. The real conundrum lies in an underlying property of the multi-component system 
held together by interactions at different sites synergistically: any one of these sites alone is 
almost certainly characterized by relatively low binding affinity, nor is it obliged to have 
evolved high specificity by nature.  
If the starting point is too low, incremental improvement on affinity by stapling does not 
guarantee the outcome of a particularly active compound that blocks native interactions by 
binding to just one site. In the Myc/Max/DNA system, numerous stapled peptides have been 
made that target two distinct interfaces, one at the leucine zipper responsible for 
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dimerization of proteins and the other at the basic region for protein-DNA binding. 
Although some hits were identified that are able to inhibit complex formation in in vitro 
assays, no peptide potent and specific enough to induce specific in vivo reprogramming has 
emerged from either group. In retrospect, a plausible explanation may be that the “native 
binding force”, so to speak, is not only made up from multiple sites, but even within each 
site is spread over a large interaction surface – over the long (>40 amino acids) stretch of 
leucine zipper, for example, of the dimerization interface. When taken out of context and 
truncated to a peptide shorter than 25 amino acids, it is hard for the minimized helix to 
recapture all of native binding force. If the hope had been that perhaps the staple would 
compensate for the lost affinity, we now know better. The moral is, each system is different, 
and only empirical data could answer the question. 
So how could we modify the strategy to better target systems that do not respond well to 
inhibition by a single helix? This question direly needs answering for the phenomenon is 
too omniscient for any researcher to ignore. Other than transcription factors, many of which 
regulate gene expression by having similar domain organization and structural motifs as 
Myc/Mad/Max, most cell-surface receptors and their respective ligand hormones also 
demonstrate the same multi-site binding behavior in their own way. The challenge is both 
intimidating and intellectually stimulating, and marks the central cause of this dissertation. 
The first two chapters describe new attempts at tackling the Myc/Mad/Max network, and –-
the latter ones at the insulin: insulin receptor system. 
Let us first return to the domain organization and structural biology of Myc/Max and 
Mad/Max (Figure 1.2). X-ray crystallography structures of Myc/Max and Mad/Max 
heterodimers in complex with DNA were solved by Nair and colleagues in 200322. Both 
complexes crystallized were formed by truncated proteins containing the bHLH-Zip 
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domains only, which proved sufficient for DNA-binding and dimerization. Specifically, Ebox 
recognition and binding occurs at the basic region achieved mostly by electrostatic 
interactions between the four arginines and lysines of the protein and DNA bases. 
Dimerization happens at helix 2 and leucine zipper regions, and the interaction is less well 
understood. Taking these data together with the NMR solution structure of Max 
homodimer23, It has been suggested that the specificity for heterodimer is governed by a 
tetrad of amino acids – Asn91 and Gln92 of Max, Arg423 and Arg424 of Myc, and Glu125 
 
Figure 1.2. Structures of Myc family dimers. (A) Crystal structures of heterodimers Myc/Max 
and Mad/Max bound to Ebox DNA and solution NMR structure of Max/Max homodimer, PDB 
codes: 1NKP, 1NLW, 1R05, respectively. (B) Close-up view of helix 2/leucine zipper where 
dimerization specificity is governed by the combination of amino acid tetrad, side chains shown in 
sticks. Max alone is able to dimerize with both Myc and Mad, as well as homodimerize, via 
electrostatic interactions, whereas homodimerization of Myc or Mad would result in electrostatic 
repulsion at the tetrad, and is thus never observed. 
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and Gln126 of Mad. Such combinations explain why the combinations of Max homodimer, 
Myc-Max and Mad-Max are possible, and that neither Myc nor Mad can homodimerize, as it 
would introduce electrostatic repulsion at the tetrad.  
In addition to providing insights on binding and specificity, these structures of truncated 
proteins also allow us to consider new means for inhibiting native complex formation. Since 
we do not need to include more 
than the bHLH-Zip domains to 
completely reconstitute 
dimerization and DNA binding, 
could we somehow obtain such a 
minimized construct that is within 
synthetic or semi-synthetic reach, to 
use as a super dominant negative? If 
there is a hydrocarbon staple 
somewhere to stabilize the artificial 
bHLH-Zip and help deliver it into 
cells, it should be able to compete 
with Myc/Max in binding to EBox 
sequence.  Such a construct would 
surely be free of shortcomings in 
low affinity or specificity suffered 
by shorter helices mentioned 
earlier. 
Figure 1.3. Schematic representation of semi-
synthetic transcription factor. The proposed 
synthetic transcription factor aims to combat Myc 
deregulation via competing for its DNA binding site 
(Ebox) and recruiting repression machinery. It 
consists of a recombinant bHLH-Zip portion derived 
from Max and a synthetic portion – stapled 
repression domain (SRD). 
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Better still, what if we staple not the bHLH-Zip core, but rather a free-standing repression 
domain such as one derived from MAD – the Sin3 interacting domain or SID, and then fuse 
the stapled repression domain to bHLH-Zip? The resulting molecule will not only be a 
dominant negative, but also an active silencer of Myc-induced up-regulation. Rather than 
simply competing for DNA binding, it would possess another business end that works in the 
opposite direction to Myc. This ambitious vision is too enticing not to try.  
Our design strategy for an artificial transcription factor with the aim of antagonizing Myc is 
illustrated in Figure 1.3. First, we will select a suitable minimized bHLH-Zip domain that 
retains Ebox-binding and dimerization capabilities from the Myc family members. In 
parallel, a stapled peptide version of a repression domain (SRD) will be developed that 
achieves high ligand binding affinity and cell penetration power.  The two independently 
obtained entities will then be covalently linked. We expect the fusion product to inherit the 
many functions of the two building blocks. First, the hydrocarbon stapled region would 
enable cellular uptake of the entire fusion and eventually nuclear localization. Once nuclear, 
the bHLH-Zip would either self-dimerize or exchange to form heterodimers with Myc family 
members, and subsequently recognize and bind to Ebox DNA sequence in a competitive 
manner to Myc/Max. The SRD would then bind to its target, Sin3, which would in turn serve 
as a scaffold for recruitment of other transcriptional co-repressors. In summary, the 
biological outcome is expected to be down-regulation of Myc-dependent gene transcription 
by an SRD-fused reprogrammer.   
As for the choice of the bHLH-Zip component, we first propose the use of the minimized Max 
bHLH-Zip since it has a short sequence and a reasonable track record in crystallography, 
and hence reasonable manageability, but there are other suitable candidates such as 
Omomyc or Mad itself. Once both components are ready, we would adapt a semi-synthetic 
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approach that connects the synthetic SRD peptide to the recombinant bHLH-Zip domain 
(Figure 1.4).  A reaction scheme known as native chemical ligation (NCL)24,25 will be 
employed for the present purposes, as this reaction generates a native peptide bond at the 
ligation site and has been used extensively in protein semi-synthesis26-30 and our laboratory 
reported the first example of native chemical ligation on a recombinant protein31.  The 
method of NCL yields a product that is “scarless” of any non-peptido functionalities and thus 
the closest imitation of a natural protein. For this reason it would be our top method of 
choice, the execution of which would entail specific requirements on peptide and protein 
chemistry. The N-terminal component, which in our case is the SRD, would need to have a 
thioester group on its C-terminus. The C-terminal fragment, the bHLH-Zip, has to begin with 
an N-terminal cysteine.  The design and methods for installing such chemistry will be 
discussed in detail later in this chapter.  
 
 
 
 
Figure 1.4. Synthesis of transcription factor via native chemical ligation.  (A) Native chemical 
ligation entails the coupling of a peptide or protein having a C-terminal thioester with a peptide or 
protein having an N-terminal Cys residue, to produce a ligated product having a native peptide 
bond at the linkage site.  (B) Ligation of an SRD with a C-terminal thioester onto a Myc family bHLH-
Zip domain in which a cysteine is engineered at the N-terminus. 
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Synthesis and Evaluation of Stapled Repression Domain Peptides 
Our first task was to obtain an active 
stapled repression domain that binds to 
Sin3 with high affinity and specificity, 
and preferably penetrates cells 
efficiently as it would have to carry 
cargo later. We examine the interaction 
between our SRD of choice and the 
transcriptional co-repressor it recruits 
in more detail (figure 1.5)32. The paired 
amphipathic helix (PAH) Domain of Sin3 
is a sequence around 100 residues long 
that is highly conserved across species 
and structurally forms a left-handed four-helix bundle. It has been shown that the PAH 
domain alone is both necessary and sufficient for interaction Mad. Between helices α1 and 
α2 is a hydrophobic cavern where Sin3-interacting domain of Mad binds via its apolar face. 
SID in turn is also a highly conserved amphipathic helix containing a unique sequence motif 
depicted in figure 1.5B. It locates at the N-terminal of Mad, and the exactly length is 
debatable as both a short and long version differing in the inclusion of the C-terminal 
residues have been reported.  Most of the residue interactions between SID and PAH are of 
hydrophobic nature, though notably the conserved glutamate near the C-terminal end of 
SID, the only charged residue in the sequence motif, engages ionic interactions with two 
lysines on Sin3. Much to our advantage, the natural SID peptide binds to the PAH of Sin3 
quite tightly; the Kd of the full domain (24 amino acids) is about 100nM, a very good starting 
Figure 1.5. Interaction between Mad and Sin3 
(solution NMR Structure). The Sin3-interaction 
domain (SID) from Mad (gold) bound to its target, 
the PAH2 domain of Sin3. PDB accession code: 1G1E.  
 13 
 
point. Hence our primary goal in designing SRD was to maximize cellular uptake while 
preserving and perhaps further enhancing binding affinity. 
Design of the initial batch of stapled peptides was under the principle of sampling as wide a 
range of staple positions throughout the sequence as possible while preserving the integrity 
of the binding face of the helix. Specifically in this case most of the conserved residues of the 
sequence motif were also left untouched (Figure 1.6). In some of the peptides we also 
mutated a few residues near the N-terminus to arginine, capped by a glutamate at the 
terminus, as it has been our experience with a large number of stapled peptides that a 
negative N-terminus and positive net charge together tend to favor greater helicity and cell 
permeation (unpublished data). Finally, there was one type of hydrocarbon cross-link – i, 
i+4 that we used for all peptides, partly for simplicity, partly for the already hydrophobic 
sequence that may become too greasy to work with using longer staples. 
Following solid phase synthesis of the primary sequence via standard Fmoc chemistry, ring-
closing metathesis was performed to close the macrocycle. To obtain compounds suitable 
for microscopy and binding assays, we appended fluorescein isothiolate cyanide (FITC) to 
Figure 1.6. Sequences of wild-type SID and stapled repression domain (SRD) peptides.  wtSID was 
made to include the full-length canonical SID sequence. SRD1, 2, 3, and  5 were mutated in the N-
terminal region to contain more arginine residues as an effort to increase cell penetration. SRDN was a 
point mutant of the identified hit SRD2 and used in binding assays as a negative control.  
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the N-terminus of the peptide after a β-alanine linker. (Here it is worth noting that it is not 
possible to N-terminally label of FITC directly after the last residue in the sequence; some 
form of linker not in the form of a natural amino acid is necessary lest side reactions occur. 
An interesting paper in 2009 addressed the issue, published just as I was making futile 
attempts at FITC-labeling without β-alanine33).  
After synthesis was complete, peptides were purified by reverse-phase high-performance 
liquid chromatography (HPLC) and ready for assays. Cellular uptake of the peptides was 
assessed by treating HeLa cells with compounds for various durations followed by confocal 
microscopy. We found the most of these SRD peptides are capable of entering cells at 10µM 
to give quite strong fluorescent signals; representative images are shown in Figure 1.7.  
Satisfied with the cell-penetrating power of SRD peptides, we proceeded to characterize 
their affinity to Sin3. The PAH2 domain of Sin3 was cloned and expressed from a pET24a 
vector that was kindly bestowed to us by Professor Radhakarishnan’s lab. We performed 
fluorescence polarization (FP) assay to measure binding of SRD peptides and Sin3 (figure 
1.8C), and found that while mostly other peptides showed binding behavior and 
dissociation constants similar to the wild-type SID, SRD2 and 5 stood out with increased 
Figure 1.7. Cellular uptake of SRD peptides. HeLa cells were treated with FITC-conjugated 
SRD peptides for 4h at 37°C in the presence of serum. Confocal microscopy revealed robust 
cellular penetration of SRD2 and SRD5. 
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affinity – Kd of 12nM and 70nM, respectively. Conveniently, these two peptides were also 
shown to be good cell penetrators earlier. 
Another experiment assessing the interaction between SRD and Sin3 we conducted was 
affinity pull-down. Here we sub-cloned the Sin3 construct to fuse it to GST separated by 
His6 and S-tag, cleavable with two proteolytic sites (Figure 1.8A). We then synthesized N-
terminally biotinylated versions of active peptides and negative mutants and performed 
affinity precipitation with the GST fusion construct. Sin3 could indeed be pulled down by 
SRD2 in a dose-dependent way, agreeing with aforementioned FP results (figure 1.8B). 
Therefore, we selected SRD2 as the primary peptide on which to implement modifications 
necessary for native chemical ligation. 
Figure 1.8. Measurements of affinity of SRD peptides to Sin3. (A) Schematic representation of 
cloning of Sin3A with various affinity tags. (B) Pull-down of Sin3 with biotinylated SRD2 and 
SRDN immobilized to streptavidin beads. Precipitated Sin3 was visualized via its GST-tag. (C) 
Fluorescence polarization readings of SRD peptides titrated with Sin3. Kd of wtSID, SRD2, and 
SRD5 was 900nM, 150nM, and 13nM, respectively.  
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Chemistry and Biology of Native Chemical Ligation 
Traditionally, native chemical ligation (NCL) requires that the N-terminal fragment, in our 
case the SRD peptide, to have a C-terminal thioester moiety attached to the α-carbon, so that 
it could react with the N-terminal thiol group on the C-terminal fragment to form a native 
peptide bond. Here a technical issue arises. Resin for peptide synthesis that can incorporate 
a C-terminal thioester is necessarily base-labile and thus not compatible with the Fmoc 
protecting group that is removed by piperidine before every coupling. In the past, 
researchers who possessed such resources used Boc-based synthesis to make C-terminal 
thioester peptides24 (Figure 1.9A). It would be difficult for us to adapt the same method 
mainly for two reasons: first, such resin requires hydrofluoric acid cleavage, which we could 
not perform in-house; second, Boc-protected non-natural amino acids for stapling were not 
available commercially. 
As NCL is a field of increasingly active research gaining more and more attention, synthetic 
routes that eliminate the need for Boc-chemistry and use of HF by varying linker chemistry 
have been developed34-37. We based our selection of new methodology on the criteria of 
safety, cost, and efficiency, and arrived at a strategy invented by Blanco-Canosa and Dawson 
in 200838,39. The method utilizes a C-terminal Fmoc-4-diaminobenzoic acid (Fmoc-Dbz) 
linker on regular rink resin that could be converted to an N-acyl-benzimidazolinone 
(termed Nbz) leaving group at the end of peptide of peptide synthesis. The Nbz group is 
capable of undergoing ligation with thiol via an N-acylurea intermediate. Through this route 
Fmoc-based SPPS is back in business (Figure 1.9B).  
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We first established in our lab the synthesis of the Fmoc-Dbz linker de novo as reported, 
which later became commercially available. We then used the linker to make a model 
peptide, the wild-type SID, and tried to obtain the final Nbz product, mainly to avoid 
complications caused by metathesis at this stage. Fortunately, we were able to make both 
the unmodified and the FITC-labeled version of the wtSID-Nbz after some troubleshooting, 
as detailed in Experimental Methods. 
Almost as foreseen, problems abound when we tried to repeat the procedure while adding 
the staple. Synthesis of FITC-SRD2-Nbz proved quite challenging, mainly because of 
incompatibility between metathesis and certain intermediates of the linker. We had to go 
Figure 1.9. Synthetic scheme for C-terminal thioester peptide to use in NCL. (A) Traditional 
methodology uses a thioester linker between peptide and resin, which necessitates tert-
butoxycarbonyl solid-phase synthesis (Boc-SPPS) and final cleavage by hydrofluoric acid. (B) 
New approach developed by Blanco-Canosa and Dawson utilizing an N-terminal acylurea group (-
Nbz) and compatible with Fmoc-SPPS. 
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through trial-and-error to sample different ordering of reactions to find one particular 
order that worked: 1) sequence elongation, 2) metathesis 3) activation of linker (-Dbz-
Nbz), and 4) FITC coupling. Finally, SRD2-Nbz and FITC-SRD2-Nbz were made. However, we 
observed rapid hydrolysis of the Nbz to give a carboxylic acid end during HPLC purification, 
which was not seen with the wtSID-Nbz peptide, and unfortunately quite detrimental to the 
yield.  
On the C-terminal fragment, i.e. the recombinant protein front, we had in our lab’s 
possession a construct expressing minimized bHLH-Zip of Max, starting with point mutation 
A12C following the start codon. According to literature40, such a construct should yield the 
N-terminal cysteine protein necessary for NCL, as it would undergo cleavage of the first 
methionine by the endogenous methionine amino-peptidase in E. coli.  We prepared the 
protein and tried to perform ligation with wtSID-Nbz and SRD-Nbz, but could not obtain any 
correct adduct. Clouding the situation further was the lack of accurate analytics to monitor 
the exact change in molecular weight of molecules: desalting of protein solution was 
probably not complete (it became especially difficult after ligation when the analyte was in 
a high salt buffer), resulting in poor ionization and broad peaks in MALDI. Because the MW 
readout was only exact to about +/- 100Da, we knew for certain that ligation was not 
happening (which would have resulted in the addition of peptide’s MW >2000Da), but could 
not tell what exactly was happening to the protein. In fact, we could not even be sure if the 
starting material protein was correct.  
B 
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In this round of problem-solving, we first designed a control C-terminal fragment: a peptide 
of sequence CRAFS. As this short synthetic peptide would certainly contain the correct N-
terminal free cysteine confirmable by LC/MS, we used it to eliminate the possibility of 
errors in the N-terminal fragment or ligation conditions. wtSRD-Nbz underwent facile 
ligation with CRAFS and yielded adduct peptide of the correct MW. Therefore we knew that 
the source of problem was with bHLH-Zip. 
With much effort we found a way of preparation of the recombinant protein that allowed 
for LC/MS analysis, and the MW we saw explained quite a lot. A +70Da modification was 
seen, which we now knew to be from addition of pyruvate to the N-cysteine to yield a five-
membered ring moiety post-translationally, a little-known but documented phenomenon41. 
After spending time and efforts to optimize experimental conditions, we were able to 
counteract the unwanted covalent modification by reaction with O-methyl hydroxylamine 
to regain the free N-Cys protein (figure 1.10).  
Figure 1.10. Covalent modification of N-terminal cysteine on Max bHLH-
Zip. A +70 shift in molecular weight was observed on LC/MS for the starting 
material Max bHLH-Zip, which matches to a previous reported phenomenon of 
pyruvate adduct formation on proteins with N-terminal cysteine. The 
transformation could be reversed by treatment with o-methylhydroxylamine. 
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Now that both components as well as reaction conditions were ready, we finally made our 
first semi-synthetic protein by NCL by fusing wtSID to bHLH-Zip (figure 1.11). The yield of 
the reaction was passable though could be improved – about 60-70% of the starting protein 
was reacted at 72h (peptide-Nbz was in excess). Part of the incompleteness came from 
trouble brought by the reducing agent. A reducing environment was necessary to keep the 
N-Cys thiol from oxidation, and a variety of reducing agents were tried including DTT, TCEP, 
and sodium 2-sulfanylethanesulfonate (“Mesna”). All of them would to some extent form 
adduct with the ligation intermediate that prevents the rearrangement step leading to the 
final product (figure1.12). It seemed a necessary evil, though efforts on how to avoid such 
side reaction would be worthwhile. 
Figure 1.11. Native chemical ligation of wtSID and Max bHLH-Zip. Left, 
LC/MS trace (MS intensity) of reaction mixture at 12 and 72hr; peak 2 contained 
the product. Right, m/z ratio of peaks 2 and 3.   
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The really coveted product, however, 
was fusion of SRD2-Nbz and FITC-SRD-
Nbz to the Max bHLH-Zip. 
Unfortunately, using the same reaction 
conditions established from above, we 
were not able to obtain substantial 
amount of this fusion protein. Firstly, 
the SRD2-Nbz peptide with or without 
FITC, already scarce to begin with, had 
very low aqueous solubility. Even at 
1mM (concentration required for NCL) 
in reaction buffer containing 6M 
guanidinine hydrochloride, the peptide 
would precipitate after some time. 
Secondly, the aforementioned hydrolysis of Nbz happened in the ligation mixture. In 
summary, SRD2-Nbz was hard to dissolve, and the little amount dissolved would soon be 
hydrolyzed to acid. The added hydrophobicity from the staple was easier to rationalize then 
SRD2’s much increased susceptibility to hydrolysis in comparison to wtSID. Regrettably this 
remains a problem that we have not solved to date, and in the meantime other types of 
ligation chemistry were explored, as will be presented in Chapter II. 
 
 
 
 
 
Figure 1.12. Product and by-product formation in 
NCL. In addition to the correct ligation product, two 
other entities were formed: ligation intermediate and 
starting material oxidized by Mesna to disulfide, both of 
which would stall ligation. 
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Experimental Methods 
Peptide Synthesis 
Preparation: resin was weighed in reaction vessels, and swollen in NMP for at least an hour. 
The amount of amino acids used was approximately six times molar excess to the loading of 
resin for normal amino acids, and three times excess for non-natural amino acids. They 
were weighed, dissolved and sonicated in appropriate volumes of NMP (sonication might be 
necessary) to yield 0.4M solution. When not in use, the amino acid solutions were stored at 
4°C. At the beginning of each day, fresh solution of PyClock was prepared at concentration 
of 0.22g/mL in NMP (0.4M). 25% of piperidine in NMP was prepared prior to starting 
synthesis. 
Synthesis: Fmoc was removed with 25% piperidine for 25 minutes. The resin was washed 
extensively with NMP four times. To drained resin, appropriate volumes of amino acid, 
PyClock, and DIPEA were added (in this order). Coupling was run for 45 minutes for regular 
amino acids and at least one hour for beta-branched amino acids (V, P, I, T), H, and all non-
natural amino acids. At the end of the coupling, resin was drained and washed thoroughly in 
NMP.  
Metathesis: resin was washed first with NMP, then DCM, finally DCE. Grubb’s Catalyst I was 
warmed to room temp. Needed amount (~7% of reaction scale) was weighed and dissolved 
in DCE and added to the resin. Reaction was run for 1.5 to 2 hours. The process was 
repeated once with freshly prepared catalyst. 
Circular Dichroism Measurement of Peptide Helicity 
The extent of helix induction in stapled peptides was measured in phosphate-buffered 
saline solution (pH 7.4) by circular dichroism spectropolarimetry, using the characteristic 
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minima at 208 and 222 nm as a well-established measure of helical character.  Less 
commonly there would be stapled peptides exhibiting other structural traits, for instance, 
310-helix characterized by a minimum centered at 207nm and a negative shoulder between 
220 and 230 nm. The CD readout was converted to molar ellipticity by inputting the 
concentration of peptide in solution, usually around 50 µM. When solubility of a peptide 
was too low to be dissolved in PBS, milli-Q water or a combination of water and acetonitrile 
was used. Besides secondary structure, CD experiments were also used in other instances to 
determine the thermal stability and melting point of a peptide via continuous recording of 
the spectrum over rising temperature. 
Measure of Peptide Cellular Uptake 
Hela cells cultured in complete growth medium consisting of DMEM, 10% FBS with 
penicillin/streptomycin were plated on chamber slides and grown to greater than 80% 
confluence and medium was removed. FITC-labeled Peptides were dissolved at appropriate 
concentrations in complete growth medium and added to cells. A DMSO control was also 
prepared following the highest concentration of peptide vehicle. Cells were then incubated 
at 37 °C for desired length of time, at the end of which medium was aspirated and cells 
washed extensively in cold PBS. Cells were fixed using 4% formaldehyde and washed again 
in PBS. The cover slips were mounted using VectaShield Hardset with DAPI.  FITC and DAPI 
fluorescence was monitored by confocal microscopy.  
Cloning, Expression, and Purification of Sin3 
The original Sin3 PAH2 construct in a pET24a vector was kindly gifted to us by Prof. 
Radhakrishnan’s group at Northwestern University. This construct did not contain any 
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affinity tag. The protein was subsequently cloned into a pET-41 Ek/LIC Vector using the 
Novagen ligation-independent cloning (LIC) kit. Oligos used in the cloning PCR were  
Sin3_LIC_Fwd, 5’ GACGACGACAAGATGTCTCTGCAAAACAATCAGCCT 3’ and Sin3_LIC_Rev, 
5’ GAGGAGAAGCCCGGTTAGGCATCTGGCAGGAACTGTCC 3’. The new construct was fused to 
N-terminal GST, His6, and S-tag.  
The resulting expression plasmid was transformed into Rosetta 2 (DE3) pLysS chemically 
competent cells using kanamycin and chloramphenicol selection. A single colony was picked 
to start an overnight LB culture at 37°C. 10mL of starter culture was used to inoculate to 
flasks containing 1L of LB.  Culture was grown at 37°C for approximately 4 hours until an 
OD600 of 0.6-0.8 was reached.  The temperature was decreased to 30°C and expression was 
induced by the addition of IPTG to a final concentration of 0.1mM.  After another 4-6 hr of 
growth at 30°C, cells were harvested by centrifugation, flash frozen by liquid nitrogen, and 
stored at -80°C until use.   
Frozen cell pellet from 1L culture was thawed on ice, and ice cold Lysis Buffer was added to 
pellet, 25-30mL/1L culture. Cells were resuspended by gentle pipetting and sonicated to 
lyse open: 10 sec on, 30 sec off for 2 min, wait for 1 minute, then repeated once. Lysed cells 
were entrifuge at 14000 rpm for 40 min. During centrifugation, Ni-NTA resin was 
equilibrated with lysis buffer (2-3mL slurry per 1L culture). Lysate was filtered with 2um 
filter, transfered to a 50mL conical tube or gravity-pull column, add equilibrated resin, and 
incubated on rock bed in cold room for 1h, turning every 15 min. The flowthrough was 
drained, and the resin was washed once with 25mL of Wash Buffer.  The bound proteins 
were eluted by washing the resin once with 1.5mL of Elution Buffer followed by 5 elutions 
with 2.5mL of Elution Buffer.   
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The elution was further purified by Superdex 200 Gel Filtration. Fractions were analyzed by 
SDS-PAGE and combined to yield GST-Sin3 in >90% purity.   
Lysis Buffer 
20mM HEPES pH 7.5 
150mM KCl 
1mM EDTA 
5% Glycerol 
1mM PMSF 
 
Wash Buffer 
Lysis Buffer, 50mM imidazole 
 
Elution Buffer 
Lysis Buffer, 300mM imidazole 
 
Gel Filtration Buffer 
20mM HEPES pH 7.5 
150mM NaCl 
5% Glycerol 
 
 
Fluorescence Polarization 
The FP Assay had to be performed within a week of purifying the protein or thawing of flash 
frozen protein aliquots.  Sin3 protein sample in Gel Filtration Buffer had been quantified 
prior to the assay using the standard BCA assay and double-checked by absorbance reading 
at 280nm, then diluted in the same buffer to 3µM working stock. The assay was performed 
using a standard opaque 384-well plate in which serial dilution of protein was made from 
the 3µM starting point and diluting at the interval of 3X, until the last protein sample 
reached a final concentration of 0.1nM. Peptides were also dissolved in Gel Filtration Buffer 
and added to each well of protein at the final concentration of 15nM and total final volume 
of <90µL. Each data point was done in triplicate. The plate was sealed with aluminum foil 
and incubated in the cold room for 0.5-1h.  
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At the end of the incubation period, fluorescence polarization values were obtained from a 
Hewlett-Packard SpectraMax plate-reader using the “Endpoint” “FP” setting and 
excitation/emission wavelengths of 485nm and 525nm.  
Pull-down Assay 
Pull-down assays were also done with protein samples that were no longer than a week old 
from purification or thawing.  
Preparation: Life Technology M280 magnetic streptavidin-coated beads were equilibrated 
in Binding Buffer and drained using the magnetic strip. Biotinylated peptides dissolved in 
Binding Buffer at 10µM were added to the beads, along with one sample treated with DMSO 
control in Binding Buffer. Immobilization of peptides was done by gentle nutating overnight 
in the cold room. 
Pull-down: on the next day, the beads were drained and washed thoroughly in Wash Buffer. 
Sin3 protein sample was diluted to desired concentration in Binding Buffer and introduced 
to the peptide-bound or mock beads. Pull-down was allowed to go for up to 3h by gentle 
nutating in the cold room. All samples were then drained and washed extensively in Wash 
Buffer. At the end of the last wash, 1X SDS Loading Buffer was added to the beads and the 
mixture was boiled at 95°C for at least 5 minutes to release bound protein. Samples were 
then run on SDS-PAGE gel to be visualized by Western blot. 
Immunoblotting: At the completion of gel electrophoresis, SDS-PAGE was transferred to 
nitrocellulose membrane using the wet transfer method in Transfer Buffer. After transfer, 
the blot was blocked in Blocking Buffer for up to 1h at room temperature, and incubated 
with primary antibody (rabbit GST Antibody #2622, Cell Signaling) at 1:1000 in Blocking 
Buffer overnight in the cold room. On the next day, the blot was washed extensively and 
 27 
 
then incubated with secondary antibody (Anti-rabbit IgG, HRP-linked Antibody #7074, Cell 
Signaling) in Blocking Buffer for 1h at room temperature. The blot was again washed 
thoroughly before visualization by addition of SuperSignal West Pico Chemiluminescent 
Substrate from Pierce. 
Binding Buffer 
Phosphate Buffered Saline pH 7.4 (NaCl = 147mM, regular) 
0.01%(v/v) Tween-20 
0.5%(w/v) BSA  
 
 
Wash Buffer 
Phosphate Buffered Saline pH 7.4 (NaCl = 500mM, high salt) 
0.01%(v/v) Tween-20 
 
SDS Loading Dye, 4X 
50 mM Tris-HCl pH 6.8 
2% SDS 
10% glycerol 
1% β-mercaptoethanol 
12.5 mM EDTA 
0.02 % bromophenol blue 
 
Transfer Buffer, 10X, for 4 L 
121.1 g Tris base 
576 g glycine 
Bring up the volume to 4 L with ddH2O 
(Add 20% methanol when making 1X solution) 
 
Blocking Buffer 
Tris Buffered Saline pH 7.4 
0.1%(v/v) Tween-20 
5% (w/v) BSA 
 
Synthesis of –Nbz Peptides 
Preparation and coupling of first residue: the Dawson Dbz AM resin (EMD Chemicals) was 
pre-swollen in NMP. Fmoc was removed by 20% piperidine in NMP. To couple the first 
residue, amino acid and HOBt and HATU (6 equivalents of resin loading) and DIPEA (9 
equivalents of resin loading) were added in that order and coupling was allowed to proceed 
for 1h. 
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Synthesis and activation: the elongation of sequence was done in regular Fmoc-SPPS 
manner as described earlier. Importantly, ring-closing metathesis needed to take place 
before the activation of linker when the free amine was intact. Upon coupling of the second-
to-last residue, the N-terminal residue was introduced using a Boc-amino acid. For 
activation of linker, p-nitrophenyl chloroformate (5 equivalents of resin loading) was added 
in DCM and left to gently agitate under nitrogen for 1h. Resin was drained and washed and 
0.5M DIPEA was added in 10mL DMF and left to react for 30min. After installation of the –
Nbz group, FITC could be coupled to the N-terminus of the peptide. In general, the order of 
installations should be as follows: 1) sequence elongation, 2) metathesis 3) activation of 
linker (-Dbz-Nbz), and 4) FITC coupling. The finished peptide was then cleaved in the 
same TFA cocktail and purified on HPLC as mentioned before. 
Expression and Purification of Max bHLH-Zip 
A pET28a plasmid containing the minimized Max bHLH-Zip with N-terminal cysteine 
(obtained from Dr. Eileen Kennedy and Dr. Jerry Hilinski in the lab) was transformed into 
Rosetta 2 (DE3) pLysS chemically competent cells using kanamycin and chloramphenicol 
selection. A single colony was picked to start an overnight LB culture at 37°C. 10mL of 
starter culture was used to inoculate to flasks containing 1L of LB.  Culture was grown at 
37°C for approximately 4 hours until an OD600 of 0.6-0.8 was reached.  The temperature was 
decreased to 18°C and expression was induced by the addition of IPTG to a final 
concentration of 0.1mM.  After another 12 hr of growth at 18°C, cells were harvested by 
centrifugation, flash frozen by liquid nitrogen, and stored at -80°C until use.   
Frozen cell pellet from 1L culture was thawed on ice, and ice cold Lysis Buffer was added to 
pellet, 25-30mL/1L culture. Cells were resuspended by gentle pipetting and sonicated to 
lyse open: 10 sec on, 30 sec off for 2 min, wait for 1 minute, then repeated once. Lysed cells 
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were entrifuge at 14000 rpm for 40 min. During centrifugation, Ni-NTA resin was 
equilibrated with lysis buffer (2-3mL slurry per 1L culture). Lysate was filtered with 2um 
filter, transfered to a 50mL conical tube or gravity-pull column, add equilibrated resin, and 
incubated on rock bed in cold room for 1h, turning every 15 min. The flowthrough was 
drained, and the resin was washed twice with 45mL of Wash Buffer.  The bound proteins 
were eluted by washing the resin twice with 2.5mL of Elution Buffer.  (Buffer compositions 
were the same as used in purification of Sin3). 
Native Chemical Ligation 
To prepare N-cysteine Max for native chemical ligation, acetone was added to the purified 
protein in Elution Buffer at 4:1 to precipitate the protein. The pellet was dissolved in 
phosphate buffered saline pH 7.4 containing 400mM o-methylhydroxylamine to convert the 
cyclized pyruvate-adduct back to the free thiol form. The corrected protein was again 
precipitated by acetone and re-dissolved in Ligation Buffer. The final concentration of Max 
in Ligation Buffer was about 0.2mM. 
wtSID-Nbz from 10mM stock in DMSO was added to the Max-containing Ligation Buffer at 
final concentration of 10mM. The mixture was stirred at room temperature for 12 – 72h and 
monitored by LC/MS. 
Ligation Buffer 
300mM NaHPO4 pH 7.8 
6M guanidinium hydrochloride 
100mM Mesna 
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Chapter II – Experimental Optimization of Semi-synthetic 
Transcriptional Factors  
 
Adapting a New Bio-conjugation Method 
Although native chemical ligation is an attractive way to create fusion proteins that does not 
introduce any non-peptide element in the product, it is neither the only method to connect a 
synthetic peptide to a recombinant protein nor the most efficient. A litany of chemoselective 
ligation or conjugation strategies have been developed in recent decades1-3, most of which 
utilize various types of naturally occurring nucleophiles from one building block, such as the 
amine of lysine or thiol of cysteine, to connect to artificially installed electrophiles on the 
other.  
Quite recently one of these methods, the maleimide – cysteine conjugation4-8, was 
successfully used to bring together two different stapled peptides in another target system. 
In the setup, depicted by figure 2.1, one peptide contains a lysine residue that was 
orthogonally protected by an Mmt group that can be removed by dilute trifluoroacetic acid. 
The free amine of the lysine side chain can then be labeled with Succinimidyl-4-(N-
maleimidomethyl)cyclohexane-1-carboxylate (SMCC) to yield a maleimide-activated 
peptide, leaving the N-terminus free for other use, e.g. fluorophore labeling. The purified 
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maleimide peptide reacts with the thiol group of the other, cysteine-containing peptide. 
Although a non-native moiety is left in the fusion product, a rather undesirable trait, this 
method offers a few advantages over NCL: the building blocks are easier to prepare and the 
reaction is more facile and foolproof. Furthermore, it allows the cysteine to be anywhere in 
the C-terminal fragment rather than confining it to the N-terminus, which greatly would 
simplify things considering how labile and promiscuous an N-Cys could be as we witnessed 
earlier.  
Encouraged by the successful use of this cysteine-maleimide conjugation method in linking 
two synthetic peptides, we proceeded to adapt it for making SRD2-bHLH-Zip. FITC-SRD2 
was re-synthesized to include an Mmt-protected lysine on the C-terminus, which upon 
sequence completion and N-terminal FITC-labeling was removed to install the maleimide 
Figure 2.1. Proposed synthetic scheme of cysteine-maleimide conjugation.  
The N-terminal peptide is functionalized with maleimide on a lysine side chain. The 
C-terminal recombinant protein, prepared via the same way as in native chemical 
ligation, contains an N-terminal cysteine. Conjugation is achieved by addition of 
sulfhydryl to maleimide.  
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group. On the protein end, Max bHLH-Zip was prepared much the same way as before. For 
the choice of reaction buffer, we found that although FITC-SRD2-maleimide was slightly less 
hydrophobic that the –Nbz version of the peptide, it was still not compatible with most 
commonly used buffers for proteins such as Tris- or phosphate-buffered saline. Fortunately 
it did not precipitate at 1mM in 6M guanidinium hydrochloride at least. As a compromise, 
however, the recombinant protein would have to be denatured for conjugation.  
After screening for conditions, we were then able to link FITC-SRD2-maleimide to N-cys 
Max bHLH-Zip. Remarkably, correction of the covalently modified N-cysteine and 
subsequent conjugation could take place in one single step without isolation of the 
intermediate free thiol-containing protein (figure 2.2). The “one-pot” reaction worked quite 
well – almost all of the starting protein would form the correctly sized conjugate with the 
peptide within 12 hours as monitored by the LC/MS (Figure 2.3). The product was stable 
and could be easily purified on HPLC and lyophilized to be obtained in powder form. We 
soon found that the reaction was also quite scalable, and before long over 10mg of semi-
synthetic protein was 
produced. Being able to 
make the chemistry work 
in such a clean and 
efficient way was very 
exciting, and immediately 
we wanted to immediately 
test the biological effects – 
cell permeability now that 
we had a stapled, FITC-
labeled compound available. However, at this point we ran into obstacles again. Solubility, it 
Figure 2.2. “One-pot” conjugation of SRD and Max. Optimal 
conditions allowed elimination of the extra step to reverse 
cyclization of N-terminal cysteine; Purified Max containing the 
pyruvate adduct could be used directly for conjugation  
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seemed, was an inescapable issue with this system. The conjugate could be dissolved only in 
pure deionized water (Milli-Q, pH~6.0) or DMSO. When the stock solution was introduced 
to any other aqueous buffer within the physiological pH range or even tissue culture 
medium, it would precipitate immediately. And once the solution was centrifuged to remove 
the precipitate from the supernatant, the latter had undetectable absorbance at 494nm 
(FITC) and hence no detectable amount of conjugate. Incidentally, acidifying the buffer to 
below pH 6 also helped the protein dissolve, although at that pH no measurement would be 
relevant.  
Many attempts such as sonication, heating the solution up, or adding in trace amounts of 
stock solution sequentially were made but none were effective at solubilizing the conjugate. 
Since it was likely that the conjugate, being formed under denaturing conditions and 
worked up in organic solvents, never had a proper chance to refold which was at least part 
of the reason for precipitation. Slightly more sophisticated experiments were done in an 
effort to promote folding, such applying the conjugate first in Milli-Q water to Ni-NTA beads 
Figure 2.3. LC/MS analysis of conjugation and subsequent purification. Left, LC/MS trace 
(MS intensity) of reaction mixture after 12h showed robust conjugation. Product was purified by 
HPLC. Right, m/z ratio of product peak.   
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or size-exclusion chromatography column and eluting slowly by slowing exchanging to a 
more suitable buffer. These attempts did not work out either, since the conjugate would 
seemingly aggregate non-specifically on the resin and not elute with these buffers.  
At this point, it was clear to us that the unmanageable physical properties of the conjugate 
were not a trivial problem and there were no obvious solutions. We took a hypothesis-
based approach and dissected the troubleshooting to two parts, looking at each fragment of 
the conjugate separately, making informed guesses on where the biggest driver to 
insolubility was, and trying to engineer modifications in that element that lead to more 
desirable properties. 
Improving the solubility of Stapled Repression Domain peptides 
Our first hypothesis was that the low solubility of SRD2 and all other SRD peptides we have 
made so far as their own entities had been carried over to the conjugate. Even if SRD2 
represents only a small part in the conjugated product, it could still significantly decrease 
the overall solubility in a number of possible ways: forming micelles, promoting 
aggregation, preventing the rest of the semi-synthetic protein from folding properly, etc. 
Thus we decided that re-designing and extending the peptide library to obtain more soluble 
peptides would be likely to result in substantial improvements in conjugate solubility while 
incurring relatively small costs in time and resources.  
As no precise method for predicting the solubility of a peptide using just the primary 
sequence (or even crystallographic/solution NMR structure) as the input existed to our 
knowledge, we made the simplifying assumption that the overall hydrophobicity would be 
positively correlated with the number of hydrophobic residues based on all the evidence 
available. This assumption did not reflect whether the exact relationship was a linear 
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addition, multiplication, or a more complex function with other variables at play, which is 
the most likely since given the helical shape of the peptide, the spatial coordinates of these 
hydrophobic residues and their interaction with neighbors would come in to play as well. If 
we had had that information and thus a prediction method that could differentiate the net 
contribution to overall insolubility by each hydrophobic residue, we would have known 
which ones to focus on to change into something less hydrophobic without sacrificing too 
much affinity to the target protein. Since we did not, we weighted the hydrophobic residues 
equally and focused our efforts on those that appeared to be less directly involved in Van 
der Waals interactions for binding (figure 2.3A). Revisit of the solution structure showed 
 
Figure 2.4. Second-generation SRD peptides aimed to increase solubility.  (A) Reviewing 
of the crystal structure of SID bound to Sin3 showed that most hydrophobic residues in SID 
were important for binding, and the few seemingly expendable ones were near N- and C-
termini.  (B) Sequences of new SRD peptides derived from previous hits, SRD2 and SRD5. (C) 
Aqueous solubility of SRD was measured by saturating the FITC-labeled peptides in PBS and 
reading the absorbance of supernatant.  
 39 
 
that the short SID helix contained many well-defined hydrophobic interactions with Sin3. 
We deemed two residues to be relatively expendable: valine at the N-terminus and tyrosine 
on the C-terminal part of the helix. The valine did not appear to be involved in much of any 
interactions, while the tyrosine looked slightly riskier to remove. Based on this thinking we 
made SRD11-14 (figure 2.3B) based on the sequences of SRD2 and SRD5 (best binders from 
initial library) by removing the N-terminal valine or mutatint the tyrosine into a charged, 
hydrophilic residue (arginine). 
 We measured the solubility of SRD11-14 in phosphate-buffered saline, and performed the 
same fluorescence polarization assay as before to monitor change in affinity to Sin3. We 
found that in comparison to their parent peptides SRD2 and SRD5, the new SRDs in general 
were more soluble. SRD11 and SRD12, based on the extremely insoluble SRD2, saw a mild 
improvement on solubility. SRD 13 and SRD14 fared better in part because their base, SRD5, 
was less insoluble.  We did not observe much adverse effect on affinity (figure 2.5) brought 
by the mutations. In fact, SRD13 and SRD14 bind with a lower Kd than SRD5. We found this 
surprising especially in the case of SRD13 vs. SRD5, the only difference being SRD13 had 
one less amino acid (N-terminal 
valine).  It was possible that the 
shorter helix became more 
structured after stapling than the 
original one, and the gain in 
secondary structure translated 
to higher affinity.  
Continuing on testing the earlier 
hypothesis, we constructed 
Figure 2.5. Measurement of binding affinity of new SRD 
peptides to Sin3. Fluorescence polarization readings of 
SRD peptides titrated with increasing concentration of Sin3. 
Second-generation SRD peptides retained affinity to Sin3 
albeit more soluble than their parent compounds. 
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maleimide-labeled derivatives of SRD11-14 and conjugated these to Max bHLH-Zip as 
before. The result was that only the conjugate containing the most soluble peptide, SRD14-
Max, could be diluted into culture medium from water in the presence of albumin without 
visible precipitation at 10µM. Interestingly this observed solubility in culture medium was 
higher than that in phosphate buffered saline, perhaps due to stabilizing effects of co-
solutes such as albumin. However, when we made the attempt to test cellular uptake, even 
SRD14 could not stay in solution at 10µM long enough for us to observe intracellular 
fluorescence – it would precipitate on the cell membrane that prevented further monitoring 
of intracellular fluorescence. On this end, the amount of change that was imposed on the 
peptide did increase solubility of the conjugate slightly, but not enough to overcome the 
hurdle.  
 
 
 
Troubleshooting in Preparation of Max bHLH-Zip 
Preventing Aggregation of Max Our other hypothesis was that denaturation of Max by 
guanidine was also a likely culprit of aggregation and insolubility. Therefore the direction 
was to modify the methodology of the preparation of protein Max bHLH-Zip such it was 
maintained under native conditions at all time, including conjugation. Firstly, in order to 
avoid the N-terminal cysteine modification that inevitably required a resolution involving 
denaturants, a mutant of Max was made to insert an alanine at the N-terminus before 
cysteine (“ACMax”). During the purification process we noticed something unusual. After 
Ni-NTA affinity chromatography, which had been sufficient to yield very pure protein in the 
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past, the gel indicated that another round of purification was necessary. We proceeded with 
size exclusion chromatography and saw that ACMax had come out in the dead volume, i.e. it 
was aggregated. This news was of great significance because we had not expected the 
“native” Max bHLH-Zip to be prone to aggregation, and could be another reason why the 
conjugate was prone to precipitation. Through our investigation it was found that ACMax 
was co-eluted from Ni-NTA column with 
massive amounts of DNA, even though 
DNase I had been added to the lysis buffer. 
Being a DNA-binding protein, ACMax’s 
strong affinity to DNA was reasonable but 
still quite problematic. At length, extra 
purification by heparin column was also 
able to separate the protein from DNA, and 
ACMax no longer eluted as an aggregated 
mass on size exclusion column (figure 2.6). 
On the peptide front, only SRD14 is soluble 
in the protein buffer in the µM range. As 
the reaction mixture developed turbidity, 
it was centrifuged and both the 
supernatant and precipitate (needed 10% 
TFA to dissolve in acetonitrile/water) 
were analyzed by LC/MS. The supernatant 
was void of any compound, and  in the 
precipitate there were Max dimer and 
 
Figure 2.6. Removal of DNA from recombinant 
Max and de-aggregation. Top, gel filtration of 
Max after His-tag purification showed aggregation 
of protein bound to DNA. Middle, DNA could be 
separated from Max using a heparin column. 
Bottom, after heparin column Max was no longer 
aggregated. 
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peptide-TCEP adduct – it appeared that upon depletion of the reducing agent by maleimide-
peptide, Max formed disulfide crosslink. In a separate effort, Omomyc, a homodimerizing 
variant of Myc3 was expressed as a GST fusion as an alternative bHLH-Zip to Max. It was 
designed such that upon TEV cleavage and removal of GST, a cysteine would be revealed at 
the N-terminus of Omomyc. Omomyc quickly precipitates after cleavage, however – not 
surprising given the poor stability of wild-type Myc on its own. 
Conjugation of Max to Other Peptides We selected from our depository of compounds the top 
cell-permeable peptides (CPP) as quantified by high-throughput epifluorescence screening 
(Verdine Lab, unpublished), functionalized them with maleimide and conjugated with Max. 
Of these CPP-Max conjugates, the SAH-P53-8 (high affinity binder to hDM2)9 version is 
particularly interesting since it would conceivably effect targeted ubiquitination of the Myc-
Max heterodimer. To date, though all conjugates have been synthesized and purified, 
insolubility of the lyophilized product, which we had at first attributed partly to the 
hydrophobicity of SRD, seems a universal trait. It may be hypothesized that Max conjugates 
do not spontaneously refold when rehydrated (unlike small, simple stapled-peptides) but 
instead aggregate and precipitate. 
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Attempts at Refolding SRD14-Max 
Because both of the previous two hypotheses could not be tested fully due to insufficient 
increase in SRD solubility, we would have to continue hunting for more variations in the 
peptide that might lead to higher gains in solubility, the uncertainty of which had been too 
great to justify further consumption of time and capital. On the other hand, through the 
exercise of implementing changes on the peptide, protein, and conjugation conditions, we 
have made observations that seemed to point collectively at one metric that was 
particularly non-susceptible to change: the denatured state of the final product. Regardless 
of what was causing the denaturation, aggregation, and proclivity to precipitate, the end 
Figure 2.7. Denaturation and refolding of Max bHLH-Zip. (A)Purified Max was dissolved in 
increasing concentration of guanidinium hydrochloride; loss of secondary structure was monitored 
by CD. (B)Denaturation curve of Max. (C)CD spectrum of Max after refolding. (D)Thermo-
denaturation curves of native and refolded Max. 
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result was one faced by many before – an incorrectly folded protein soluble in organic 
solvents or denaturants only.  Occasionally denatured proteins could be refolded and re-
solubilized under native conditions, typically done through dialysis, rapid dilution, or 
column-assisted refolding10-16. 
Since even “native” ACMax was prone to aggregation, we used it as a starting point to 
practice refolding. We had discussed of the use of Ni-NTA and size exclusion 
chromatography in an attempt to provide solid phase support for the conjugate during 
refolding. Rapid dilution was not met with much success, either. The next thing we tried 
was step-wise dialysis. First, denaturation curve of ACMax by increasing concentration of 
guanidinium hydrochloride was constructed using circular dichoism to monitor loss of 
secondary structure. The denatured protein was then dialyzed from 6M to 2.5M 
guanidinium hydrochloride, which was the point of inflection on the denaturation curve, 
and further dialyzed into PBS. The protein solution remained clear, and CD measurements 
showed more secondary structure, albeit different compared to the native protein.  
The same conditions did not work, however, when applied to the conjugated product. As 
regular conditions and buffered failed, we conducted a screen of additives in buffer that 
have been reported to stabilize and promote folding of protein in a 94-well format, where 
denatured conjugate was rapidly diluted to different buffers. The readout was absorbance 
at 340nm measuring turbidity. Many conditions were screen in a combinatorial way, but no 
satisfyingly clear result was seen. 
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Topic Closing Remarks 
We have created multiple versions of the SRD-bHLH-Zip fusion protein envisioned in 
Chapter I using both native chemical ligation and maleimide-cysteine conjugation; however, 
these semi-synthetic proteins have not been tested for hypothesized activities due to 
limitations of their physical properties. The knowledge gained from improving SRD affinity 
and solubility, as well as the methodologies established for ligation or conjugation, should 
be applicable to future efforts on the ultimate goal. Mainly, there are three directions in 
which improvements can be made: first, SRD could be further optimized either by scanning 
of more variations of hydrophobic residues, or by switching the current all-hydrocarbon 
staples with a newly developed amino-stapling system that generally incurs less 
hydrophobicity in product peptides (Hilinski and Verdine, unpublished data). Second, as 
mentioned in chapter I, other bHLH-Zip domains may be used in lieu of Max. This effort may 
be particularly worthwhile given Max’s propensity to aggregate as observed. The new 
candidate need not be within the Myc/Max/Mad family – possession of comparable 
dimerization domain is good enough, since DNA recognition (basic region) could be 
engineered. Third, more soluble building blocks may enable conjugation or ligation under 
native conditions to avoid need of refolding.  
 
Experimental Methods 
Maleimide-peptide Synthesis 
Maleimide-containing peptides were synthesized using standard Fmoc-SPPS conditions as 
described in Chapter I with a few additional steps. Before the beginning of the actual 
sequence, an Mmt-protected lysine was installed at the C-terminus followed by a linker (e.g. 
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PEG(2)). The peptide was then elongated and metathesis was performed after sequence 
completion. Afterwards, resin was subjected to treatment with 1% TFA, 4% TIS, and 95% 
DCM for 2 min and drained. The process was repeated with fresh reagents five to six times 
or until no longer orange color was observed, a signal of complete removal of the Mmt 
protecting group. SMCC (Pierce) was then coupled to the deprotected lysine side chain by 
addition of 3 equivalents of material and 5 equivalents of DIPEA, gently agitated under 
nitrogen for 4h. After SMCC coupling, the N-terminus of the peptide could be deprotected 
and labeled with FITC as usual. The purification process using HPLC was the same for 
maleimide-peptides as other stapled peptides.  
Cysteine-Maleimide Conjugation 
N-cysteine Max bHLH-Zip was expressed and purified as described in Chapter I. After Ni-
NTA affinity purification, Max in Elution Buffer was precipitated with acetone at -20°C 
overnight. Pelleted Max was dissolved in Conjugation Buffer at a final concentration of 
0.2mM and incubated at room temperature for 0.5h in order to first reverse the covalent 
modification by pyruvate. Then maleimide-containing peptide was added to the protein 
solution at a final concentration of 1mM. Conjugation was allowed to proceed overnight 
with gentle agitation at room temperature. Reaction completion was checked by LC/MS 
analysis, and the crude product was purified on reverse phase HPLC after desalting. Pooled 
fractions were dried using speedvac and lyophilized into powder form. 
Conjugation Buffer 
400mM o-methylhydroxylamine 
6M guanidinium hydrochloride 
150Mm sodium phosphate pH 7.8 
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Cloning, Expression, and Purification of ACMax 
The ACMax construct was obtained by site-directed mutagenesis using Stratagene’s 
QuickChange kit and alanine was inserted to the N-terminus before cysteine. ACMax was 
expressed and purified following the same protocol as described in Chapter I. After 
purification by Ni-NTA, it was noticed that the protein sample contained large amounts of 
DNA (A260/280 = 1.8). Addition of DNase I into the Lysis Buffer did not eliminate the DNA 
effectively.  
Pooled elution from Ni-NTA was then run on HighTrap heparin column (GE) and exchanged 
from Heparin Buffer A to Heparin Buffer B (high salt). This step was able to separate ACMax 
from DNA by disrupting their binding with high salt concentration. Pooled fractions from 
heparin column were loaded to Superdex75 gel filtration column in order to exchange back 
to a low salt buffer (Gel Filtration Buffer). Fractions from gel filtration were confirmed to be 
the correct, non-aggregated and DNA-free ACMax by SDS-PAGE and new A260/280 readings. 
Heparin Buffer A 
20mM HEPES pH 7.5 
300mM KCl 
5% Glycerol 
1mM DTT 
 
Heparin Buffer B 
20mM HEPES pH 7.5 
2M KCl 
5% Glycerol 
1mM DTT 
 
Gel Filtration Buffer 
20mM HEPES pH 7.5 
150mM KCl 
5% Glycerol 
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Refolding of ACMax 
Chemical Denaturation Curve: Purified ACMax was treated with increasing concentration of 
guanidinium hydrochloride. At each concentration, circular dichroism of the protein sample 
was measured and the molar ellipticity at 222nm was used as an indication of decrease in 
secondary structure. By plotting molar ellipticity at 222nm against the concentration of 
guanidinium hydrochloride and taking the point of inflection, the “critical” concentration of 
guanidinium hydrochloride at which half of the protein was denatured as found to be 
2.5mM. 
Refolding and Analysis of Thermo-stability of ACMax: Completely denatured ACMax (in 6M 
guanidinium hydrochloride) was refolded by stepwise dialysis: first into Gel Filtration 
Buffer with 2.5mM guanidinium hydrochloride, then 1M, then eventually achieving 
complete removal of guanidinium hydrochloride. Refolding was confirmed by circular 
dichoism. In addition, CD experiments were also used to the melting curve of ACMax and 
continuous recording of the spectrum over rising temperature range of 20 – 90°C. 
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Chapter III – Design, Synthesis, and Screening of a Library of 
Stapled Insulin Receptor Binding Peptides 
 
Introduction 
Diabetes is one of the most common and costly chronic diseases worldwide, and its 
prevalence has been growing at a faster pace in recent decades due to an exploding and 
aging global population, urbanization, and the obesity epidemic resulting from unhealthy 
diet and sedentary lifestyle. The United States, as with many other first world countries, has 
not fared better than poorer nations in either prevalence or societal impact of diabetes. In 
the latest CDC release of national diabetes statistics, 8.3% of the U.S. population is affected 
by either Type I or Type II diabetes. Healthcare expenditures directly imposed by the 
disease exceeded $218 billion annually as of 2011. Since diabetics are at elevated risk of 
other serious complications such as cardiovascular disease, stroke, hypertension, etc., 
quality of life is eroded further. Related medical costs and loss of productivity amount to 
additional economic burden and profound social problems. These facts underscore the 
urgency of deciphering diabetes at a molecular level as well as adapting advanced chemical 
toolkits so as to yield more effective therapeutics for controlling the disease. 
Understanding the biology of diabetes requires capture of the motion picture that is the 
insulin signaling pathway. Binding of insulin to the transmembrane insulin receptor (IR) 
 51 
 
induces conformational changes within the receptor, which result in auto-phosphorylation 
of intracellular β-subunits and activation of kinase activity of IR1,2 and subsequent tyrosine 
phosphorylation of its substrate IRS proteins3,4. Much of the distal signaling involves 
activation of phosphatidylinositol 3’-kinase (PI3K) by docking of its p85 subunit to tyrosine-
phosphorylated IRS-1 and IRS-2, which in turn leads to phosphorylation of protein kinase B 
(PKB/Akt) and downstream responses of glucose uptake and glycogen synthesis. 
Additionally, activated IRS-1 is also coupled the Ras pathway and up-regulation on gene 
expression4-8. Various kinds of disruption at the front end of this signaling pathway, e.g. lack 
of insulin secretion or insensitization of the receptor to insulin, mark the pathological origin 
of both Type I and Type II diabetes. Despite extensive effort over decades, the molecular 
mechanism of regular insulin binding and IR activation and of changes in disease states 
remains unclear. 
As a member of the tyrosine kinase receptor family, the insulin receptor is a glycoprotein 
consisting of two  and two  subunits (22) covalently linked by disulfide bonds9. The IR, 
which is synthesized as a single chain proreceptor, undergoes glycosylation and 
dimerization in the endoplasmic reticulum followed by Furin cleavage into the α- and β-
chains in the Golgi apparatus. The IR ectodomain is comprised of two full-length  subunits 
and the N-termini of two  subunits; the remaining C-termini of the  subunits contain the 
transmembrane (TM) domains and cytoplasmic tyrosine kinase (TK) domains10,11. Insulin 
binding determinants reside exclusively within the ectodomain, which consists of N-
terminal two leucine rich repeat (L1 and L2) domains separated by a cystein-rich (CR) 
domain12,13 as well as C-terminal three fibronectin type III (Fn0, Fn1, and Fn2) domains14-16.  
Additionally, an insertion domain residing in Fn1 contains a Furin cleavage site. Upon 
cleavage of the proreceptor, the - linkage is maintained by disulfide bonds between 
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Cys524 in each Fn0 domain17 as well as those between Cys682, Cys683, and Cys685 in each 
insertion domain18,19, while the - hetero-dimer is bridged by a single disulfide link 
between Cys647 in Fn1 and Cys872 in Fn2 domain20 (Figure 3.1A).  
 
Although insulin, the first peptide hormone visualized by x-ray crystallography21, has been 
extensively explored structurally over the past 50 years, crystal structures of the L1-CR-L2 
domain22 and the whole ectodomain of IR23,24 were not solved until 2006. Furthermore, 
neither of these constructs adopts a conformation conducive to high-affinity insulin binding. 
Figure 3.1. Representative domain structure of the insulin receptor. (A)Two  subunits and 
the N-termini of two  subunits form the ectodomain, whereas the C-terminal  subunits contain 
the transmembrane  (TM) domains and tyrosine kinase (TK) domains. The ectodomain consists 
of the N-terminal leucine rich repeats and cysteine rich (L1-CR-L2) domains and three C-terminal 
fibronectin type III domains (Fn0, Fn1, and Fn2). -CT resides at the C-terminus of the IR -chain. 
(B) Insulin binding sites on IR. Site 1 is formed by the central -sheets of L1 and CT, and site 2 is 
the loop between Fn0 and Fn1. 
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Thus, high-resolution three-dimensional structural information of the insulin/IR binary 
complex continues to spark enormous interest. The current interaction model was obtained 
by indirect methods such as alanine scanning mutagenesis25,26, photoaffinity labeling27,28, 
chemical cross-linking29,30, phage-displayed peptide probes31,  or monoclonal antibody 
probes32-34. Insulin binding to the dimeric holoreceptor is characterized generally by high 
binding affinity (pM range) and negative cooperativity35,36. It is proposed that there are two 
insulin binding sites on the IR: site 1, which contacts the classical binding surface of 
insulin37,38, and site 2, which was predicted to bind the hexamer-forming face of insulin39,40. 
As shown in Figure 3.1B, site 1 on one monomer of the IR is close to site 2’ on the second 
monomer, and binding of insulin to site 1 induces its subsequent binding to site 2’. This 
causes a conformational change of the IR ectodomain that leads to a reduction of distance 
between the two intercellular TK domains, thereby promoting autophosphorylation. Several 
lines of evidence have shown that 
binding site 1 on the IR is formed 
by the central -sheet of the L1 
domain41,42 and the C-terminal -
subunit peptide (-CT, aa704-
aa719)26,30. Site 2 is likely to be 
located at the loop region 
between Fn0 and Fn1 since it 
faces site 1 of the other monomer 
in the dimeric structure of the IR 
ectodomain24.  
Insulin receptor binding peptides 
Figure 3.2. Structure of the a-CT segment of IR and 
sequence comparison with S371. Top, close-up view of 
interaction between αCT (blue) and L1 (teal). Bottom, 
sequence comparison of αCT and S371. Black square 
indicates residues engaged in L1 binding. 
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had previously been evolved by phage display from randomized peptide libraries ranging in 
size from 20 to 40 amino acids. 31 Such primary binders were then subjected to defined 
mutagenesis procedures based on analysis of sequence motifs, consensus regions, and 
multiple independent hotspots on the receptor to yield secondary and tertiary libraries. Hits 
from all libraries were grouped to two major categories corresponding to two different 
binding sites on IR as determined using a competition ELISA assay.  From these libraries 
came S371, a prototypical site 1 peptide with the highest affinity to the IR (kd = 40 nM) and 
predicted to form a helix. Of particular interest is the similarity in sequence motif between 
S371 and the alpha subunit C-terminus (-CT) of the IR (figure 3.2.), which had been 
speculated to be helical and play a role in ligand binding and receptor activation for quite 
some time. Several lines of evidence pointed to a model in which -CT together with L1 of 
the other monomer forms an insulin biding site: 1) photoactivated cross-linking 
experiments43-46 that associate -CT with insulin at residues A3, A8 and B25, while insulin 
B24 can crosslink to L1, 2) mutagenesis26,47 that showed Phe714 of -CT is critical for ligand 
binding, and 3) study of mini-receptor22,48,49 consisting of only L1-CR-L2 that does not bind 
insulin, to which a mere addendum of -CT regains ligand binding with similar affinity to 
the soluble ectodomain. Excitingly, recent revelation of the -C-terminal structure24 
confirmed its alpha-helical nature as well as binding to the beta-sheets L1 domain in trans. 
Although this piece of long-missing crystallography information closed the case of -CT’s 
place and associations in the ligand-free receptor, it raises more questions on the structural 
perturbations of ligand binding and interactions between -CT, L1, and insulin. 
Furthermore, how does a surrogate peptide bind to the IR via a sequence- and perhaps 
structure-mimicry of -CT, and could this surrogate ever be modified such that its binding 
affords a full transformation of receptor configuration resulting in activation much like the 
natural ligand? Thus it comes as no surprise that we select S371 as the lead compound for 
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enhancement with a hydrocarbon cross-link, for the goals of chemical optimization of the 
peptide and elucidation of its bound structure to the receptor. Through this practice we 
hope to arrive at compounds with greater potency as either agonist or antagonist to the IR 
which, beyond the obvious therapeutic potential, would also help unveil mechanism of IR 
activation at a greater detail than current knowledge provides. 
 
Design and Synthesis of Stapled Insulin Receptor Binding Peptide Library (SIRB) 
As discussed in previous chapters, the design of a stapled peptide library typically starts 
with a careful examination of the known ligand-bound structure of the target and selection 
of residues on the ligand (α-helix to be modified) that would endure replacement by non-
natural amino acids with minimal cannibalization of natural interactions. A certain face of 
the helix away from the interface usually presents most sites suitable for modification. Such 
has been the logical thinking and historic holy grail in the burgeoning stapled peptide space, 
but recent studies prompt one to think outside the box. First, Phillips and colleagues at 
Pfizer reported stapled versions of a coactivator peptide binding to the estrogen receptor 
(ER) in 201150. Importantly, crystal structure of the peptide-ER complex showed that the 
hydrocarbon crosslink is in fact part of the expanded interface, and actively engages 
hydrophobic interactions with the receptor that are unattainable to the unmodified peptide. 
Shortly after, structure of a previously published stapled P53 peptide bound to Mdm2 was 
solved, revealing similarly an active role of the staple in forming new contacts with the 
protein51. These discoveries add to the reasons for the dramatic increase in affinity 
oftentimes observed with these molecules – that beyond exerting physical constrain of the 
helix conformation, the staple itself could pick up additional dimensions that augment the 
existing protein-protein interactions. It is arguably a redeeming trait of the lengthy, 
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hydrophobic patch that is the crosslink; the grease ball that aggravates solubility issues to 
such problematic extents is not inherently without its merits (sometimes). 
Thus, one may see the caveat of purposely avoiding placement of the crosslink at or near 
interacting residues or faces of the helix. The new “anything is possible” principle is, 
however, as exciting as it is hard to execute, for the sheer number of possibilities pose a 
significant challenge to the intellectually mundane but labor- and resource-consuming act of 
peptide synthesis.  Furthermore, the screening element becomes more pronounced in a 
stapled peptide endeavor with larger library size, much like conventional fishing of small 
molecules, and the design part is diminished. Length of the original helix, as well as the 
resolve for how comprehensive the library should be, dictates the scale of the synthetic 
project. S371 spans 16 residues, a length that renders a comprehensive sampling of the 
hydrocarbon crosslink positions, as discussed below, elaborate yet still achievable. In light 
Figure 3.3. Schematic representation of all types of hydrocarbon crosslink implemented on 
peptide S371. (A) Six types of hydrocarbon crosslinks featuring single staple (i, i+3; i, i+4; i, i+7) 
and stitching ( i, i+4+4; i, i+4+7, i, i+7+7.). Red spheres represent non-natural amino acids. 
(B)Example of staple “scanning” through the S371 sequence for i, i+4. 
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of previous examples, we envision that adding a hydrocarbon crosslink on S371 will impart 
important properties: first, greater secondary structure that will lead to higher target 
affinity; and second, resistance to proteolytic degradation, higher bioavailability, and longer 
serum half-life will improve pharmacokinetics on the therapeutic perspective.  A final, more 
ambitious trait that may be actualized by this chemical modification is that the hydrophobic 
nature and lengthy stretch of the cross-link may enable participation in Van der Waals 
interactions with the FnIII-1/FnIII-2 loop at site 2, engaging an interface not accessible to 
an unmodified site 1 peptide. As such, it is of particular interest to include as many staple 
sites as possible in this case, given that the helix alone is known to solicit only a limited set 
of interactions.  In order to fully explore the physicochemical space reachable by the 
hydrocarbon cross-link, we have adopted a comprehensive scanning approach in creating 
the peptide library.  Distinct combinations of α, α-disubstituted amino acids are used to 
form stapled insulin receptor binding (SIRB) peptides with cross-links of various length and 
composition (Figure 3.3).  All seven types of hydrocarbon crosslinks that our laboratory has 
developed to date are included in the library design: i, i+3; i, i+4; i, i+7; i, i+4+4; i, i+4+7; i, 
i+7+4; and i, i+7+7. In each series, “i” starts at the C-terminus of the peptide and moves forth 
until the other end of the crosslink reaches the N-terminus. This way all possible positions 
for staple incorporation can be sampled.  Stapled peptides were made by solid phase 
synthesis using standard Fmoc chemistry as described previously52.  
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Screening of SIRB library and Validation of Hit Peptides 
The importance of a robust and reliable screening system is paramount in such an all-out 
expedition. A direct read-out of affinity to the receptor is highly desired, and the assay to be 
relatively scalable to accommodate throughput of the library. Here again implementation of 
routine practice – that is, recombinantly obtaining the target protein and quantitatively 
determining the Kd of each peptide via fluorescence polarization, isothermal titration 
calorimetry, or other binding assays – encounters unusual impediment, because the insulin 
receptor protein is, in short, hard to get a hold of, especially for large enough quantities to 
conduct the screening (will be addressed in detail in Chapter 4). Drawing example from the 
literature31,53-55, the next-best measurement is of activity of the peptide upon engaging the 
receptor (agonistic/antagonistic effects, etc.). To this end, changes in the insulin signaling 
cascade in the presence of peptide can be monitored by cell-based assays that circumvent 
the need of purified IR protein. 
As mentioned before, the primary signal relay that initiates at the insulin receptor is 
phosphorylation of the protein itself and downstream effectors or “nodes”. One of the most 
commonly assessed nodes in the IR pathway is PKB/Akt1, a growth-promoting, anti-
apoptotic protein responsible for transmitting the mitogenic and metabolic effects of 
insulin56-60. We therefore wished to evaluate the activity of SIRB peptides by measuring the 
changes in phosphorylation level of Akt1. The first cell line we selected to use for screening 
is HepG2, human liver cancer cells which express high levels of IR and Akt161-63.  For initial 
screening, each peptide in the library was tested for both antagonistic and agonistic effects 
using a sandwich ELISA assay kit (Cell Signaling) by measuring phosphorylation of Akt1 at 
Ser473 performed on HepG2 cells. Two measurements were made on each compound: 1) 
treatment of cells with insulin and peptide together to reveal antagonism on the receptor; 2) 
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treatment with peptide alone to reveal agonistic effects. We first validated the assay with 
unmodified S371 and established the starting point activity: at 10 µM it demonstrated 20% 
reduction of the maximal phosphorylation level caused by insulin, and no trace of any 
increase in phosphorylation on its own. This observation is in slight contradiction with 
published agonistic attribute based on increase in kinase activity of IR in vitro31. 
Nevertheless, we do note that although S371 has a high affinity to IR, it can barely induce 
downstream effects such as lipogenesis in rat adipocytes, which may reconcile with the 
result of no increase in downstream Akt phosphorylation. With respect to our stapled 
peptides, one or two peptides emerged as antagonists in each crosslink series. The hits and 
their corresponding reduction of Akt phosphorylation at 10 µM are summarized in Figure 
3.4. Intriguingly, one of these peptides, SIRB-D2, exhibited significant agonistic effects at a 
concentration of 100 µM, leading up to 60% of the maximal insulin-induced level (Figure 
3.4B). We hypothesize that at such a high concentration, the SIRB-D2 peptide may yield a 
Figure 3.4. SIRB antagonism and agonism. Effects of SIRB on insulin signaling were measured 
by ELISA specific for Akt-S473 phosphorylation. (A)HepG2 cells were treated with 10 µM peptide 
in the presence of 50 nM insulin. In each series, there emerged SIRB peptides that exhibit greater 
than a 60% reduction of the insulin-induced signal. (B)HepG2 cells were treated with 10 or 100 
µM peptide in the absence of insulin. SIRB-D2 at 100 µM exhibits agonism equal to approximately 
60% of the insulin-induced signal. All readouts (in RLU) were normalized to the signal by 50 nM 
insulin alone with vehicle as baseline. 
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non-covalent dimer equivalent capable of engaging both binding sites on IR as insulin does, 
which still needs to be further demonstrated by complex structure of peptide bound IR 
ectodomain. No similar agonistic effect was observed with any other compound in the 
library.  
The choice of HepG2 cells and Akt1 as a first line of screening was based on the ease of 
access: the cell line was commercially available and the antibodies of Akt are widely used 
and very well validated. But we needed a more direct assessment of the IR phosphorylation 
in order to be confident on the peptides’ effects on distal signaling stated above. 
Furthermore, Akt1 is a node shared by many crisscrossing cellular circuits such as AMPK, 
mTOR, ErbB/HER pathways, etc.56,64-66  Therefore off-target activity could not be excluded 
from the possible explanations for the observed effects. We were fortunate to have received 
in the nick of time a generous gift from Professor Morris White’s lab at Boston Children’s 
hospital - a stably transfected CHO-IR cell line from which phosphorylation of IR could be 
singled out with ease at the expression level of 10,000 receptors per cell. Antibodies that 
recognize the phosphorylated receptor cannot distinguish IR from insulin-like growth 
Figure 3.5. Validation of SIRB peptides. Effects of SIRB peptides on Phospho-IR level were 
detected by western blot. (A)CHO-IR cells were treated with 10 µM peptides in the presence of 50 
nM insulin. (B) CHO-IR cells were treated with increasing concentration of peptide in the absence 
of insulin. Results are shown in comparison of stimulation by 50nM insulin. Total IR levels were 
measured as control. 
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factor 1 receptor (IGF1R), so the fact that little to none IGF1R is expressed in this cell line 
was quite convenient. The entire SIRB library was again screened for auto-phosphorylation 
of IR, with blotting of total IR-β as an internal control of loading. The results are aligned 
with previous observations on Akt1 to a satisfactory degree. On the antagonistic perspective, 
all of the pre-identified peptides that reduced phosphorylation signals of Akt1 in the 
presence of insulin also demonstrated similar effects on the IR, and no antagonists of IR 
alone were found that had not surfaced from the Akt1 ELISA (figure 3.5A) As for agonistic 
activity in the absence of insulin, there were surprises (figure 3.5B). Peptide SIRB-D2 
indeed induced phosphorylation of IR in a dose-response manner, as expected from its 
effect on Akt1. There were, however, more peptides that are able to induce IR auto-
phosphorylation but had seemingly no observable effect on Akt1: SIRB-D5 and SIRB-E2. 
This curious discrepancy may be indicative of the peptides’ different potencies, i.e. how far 
down the pathway the signal is transmitted depends on the intensity and duration of the 
original event at the receptor.  
We also quantified the dose-response behavior of the most active antagonist SIRB-B5 on 
inhibiting insulin-induced autophosphorylation of IR and phosphorylation of Akt with 
ELISA (figure 3.6). It was observed that SIRB-B5 exerts similar concentration-dependent 
antagonistic effects on both IR and Akt, with an IC50 value of 1.8 µM. Interestingly, at the 
maximal dose of 100 µM peptide, autophosphorylation of IR is reduced to about 6% of 
control, whereas Akt phosphorylation is reduced to a lesser extent, 16%. Again, a possible 
explanation for the differential plateau values is that phosphorylation of Akt1 is controlled 
by many other pathways as well and thus difficult to abolish completely. 
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After using these independent 
measurements of phosphorylation 
levels as two rounds of screening and 
obtaining consistent results (for the 
most part), we felt confident of the 
peptides identified as either agonists or 
antagonists of the IR. In addition, 
circular dichroism revealed an increase 
in helicity of active SIRB peptides 
compared to unmodified S371 (Figure 
3.7). Interestingly, peptide A2, one of 
the antagonists, shows an intense 
minimum of molar ellipticity around 208nm, characteristic of a 310 helix. None of the 
peptides in other crosslink series exhibits such structural trait. As we move down the lists of 
series, i. e. going from relatively short and simple to longer and more constrained crosslinks, 
we observe the general trend of increasing helical character (compare B5, C1 and D2). Such 
results are in accordance with our 
general experience with stapled peptides, 
whose secondary structure is usually 
positively correlated with staple length 
and rigidity.  
Figure 3.8 shows a synthesis of the 
findings this far. Sequences of peptide 
hits are shown grouped in the two 
 
 
 
 
 
 
 
 
Figure 3.6. Dose-response of antagonist SIRB-
B5. CHO-IR cells were treated with 50 nM insulin 
and increasing concentrations of SIRB5. ELISA 
assays of phosphor-IR Y1150/1151 and phosphor-
Akt S473 were performed with cell lysates. 
Figure 3.7. Secondary structure of S371 and 
select SIRB hits. CD spectroscopy of active SIRB 
peptides in each cross-link series illustrates the 
increase in helicity brought by synthetic 
modification.  
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categories of antagonists and agonists. Two points should be made here: 1) Although one or 
two peptides emerge from each type of hydrocarbon staple series as hits, all of them 
regardless of series or category contain the non-natural amino acids for stapling at 
converging sites, which if traced back to the original S371 sequence localize to only eight 
out a total of 16 residues. Structurally speaking, these sites concentrate on a particular face 
of the helical wheel, and we see no peptides that feature the staple on the opposite face 
being particularly active. 2) Though all hits share said localization of staple positions, only 
the longest crosslinks seem to confer any agonistic effects (SIRB D2, D5, and E5 are i+4+7 
and i+7+7). Coinciding with this result is the trend of increasing helicity discussed above; 
thus it appears that a more structurally constrained peptide is more prone to antagonize the 
receptor. Yet as mentioned in the introduction, longer staples are themselves source of 
contact surface in addition to simply rigidifying the peptide. The question of whether the 
staples in the agonist peptides are able to pick up IR residues either nearby on the L1 
domain or from the loop in the junction of Fn0/FnI domains of the purported Site 2 is both 
highly relevant and difficult to answer without direct structural information. A third 
possibility is that peptides of the later series, whether by virtue of being more structured or 
more hydrophobic thanks to their crosslinks, experience a higher proclivity of self-
dimerization or oligomerization when put in contact with the receptor, and therefore 
engaging the two sites on IR and causing conformational changes much the way insulin does. 
Figure 3.10B attempts to shed light to the currently structure-less situation by modeling 
S371 based on the known position of IR αCT, using conserved residues as anchor points. 
The eight residues where staple “hotspots” were found are highlighted. If the hypothesis 
that S371 and thus the SIRB peptides mimic αCT in binding to the L1 domain is correct, and 
that the orientation of the peptide is as predicted, then it is no surprise that the “hotspots” 
are where they are: first, a staple placed there avoid clashing with the L1 surface directly; 
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second, extending on the back of the helix away from L1, the staple is positioned to either 
reach out for contact with Site 2 or serve as a scaffold for self-assembly via hydrophobic 
interactions, i.e. the dimer- or oligomerization scenario stated above.  
In summary, screening of SIRB library by ELISA of Akt1 phosphorylation identified peptides 
that either antagonize insulin signaling or agonize the IR pathway in the absence of insulin. 
Independent screening of receptor auto-phosphorylation by Western blot confirms the 
activity of hit peptides comes at least in part from directly interacting with IR. Secondary 
structure measurements and modeling of the peptide sequence based its alleged object of 
imitation – IR αCT- help rationalize the relations between crosslink chemistry and observed 
activity of the peptides, but more questions are raised along the way. How can the structural 
model be supported before direct evidence of the complex structure becomes available? If 
the hypothesis holds, what are the broader ramifications on the peptides’ cellular activities, 
Figure 3.8. Summary of active SIRB peptides. (A) Sequences of antagonists (shaded in salmon) 
and agonists (shaded in green). (B) The interaction model between S371 (green) and L1 domain 
(insulin binding site 1 on IR, teal) of the IR. Staple hotspots are shown in magenta spheres. 
Residues involved in direct interactions between S371 and the IR as well as residues in Fn0/Fn1 
loop (insulin binding site 2 on IR, in wheat) that may interact with staples are shown in stick 
rendering. 
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especially their selectivity or promiscuity with respect to other receptor tyrosine kinases? 
Furthermore, are there ways to optimize the potency of the active peptides? These are the 
questions that Chapter 4 seeks to address.  
 
Experimental Methods 
Peptide Synthesis 
SIRB Library peptides were synthesized using the standard Fmoc-SPPS protocol and 
purified on reverse-phase HPLC as described in Chapter I. 
Cell Culture 
HepG2 cells (ATCC) were maintained in complete growth medium consisting of DMEM, 10% 
fetal bovine serum (FBS) and streptomycin/penicillin. Cells were passaged when reaching 
greater than 80% confluence (on average 3-4 days) and split 1:6 per passage. 
CHO-IR cells (from Prof. Morris White at Boston Children’s Hospital) were maintained in 
complete growth medium consisting of Ham’s F-12, 10% FBS and streptomycin/penicillin. 
Cells were passaged when reaching greater than 80% confluence (on average 2-3 days) and 
split 1:10 per passage. 
Phospho-Akt1 ELISA 
Preparation: insulin stock solution at 50µM (0.3mg/ml or 30mg/100ml). To make stock: 
dissolved 10mg in 1 ml 0.01N HCl, heat at 37C to dissolve, then added to 32mL PBS, sterile 
filtered and  stored at -20C. Working stock would stay in good quality for 1 month at 4°C. 
HepG2 cells grown to 80% confluent in 10cm plates or 6-well plates were serum-starved in 
DMEM (penicillin/streptomycin added) overnight. On the next day, the following solutions 
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were prepared: 50nM insulin in complete growth medium (from 50µM stock), 10µM or 
100µM peptide in complete growth medium (from 10mM DMSO stock), and vehicle (the 
highest concentration of DMSO used in peptide samples).  Old media was removed and cells 
were treated with appropriate compounds. For measurement of antagonism, the vehicle 
was used to create baseline, and the 50nM insulin solution was used to give maximal 
amount of signal (100% phosphorylation). Each of the peptides was given in combination 
with 50nM insulin. For measurement of agonism, the baseline and maximal level of 
phosphorylation were obtained the same way. Each of the peptides was given along in the 
absence of insulin. Cells were incubated at 37°C under 5% CO2 for 15 min for antagonism 
and 30 min for agonism. 
At the end of treatment, media was aspirated and cells were washed with ice cold PBS, and 
subsequently lysed using Lysis Buffer (from 10X Lysis Buffer, Cell Signaling; 1mM PMSF 
added prior to use). Cells were incubated in Lysis Buffer plates/wells in the cold room with 
gentle rocking for 10 min, then subjected to quick sonication. The cell lysate was then 
centrifuged at 12,000rpm for 10 min in the cold room. The clarified lysate was collected and 
aliquots were flash frozen in liquid nitrogen and stored at -80°C until use.  
For the phospho-Akt1 ELISA assay, clarified lysate was first quantified using the standard 
BCA method, and all samples were adjusted to have the same total protein concentration. 
All samples were then diluted with Sample Diluent (from phospho-Akt1 S473 ELISA kit Cell 
Signaling) at 1:1, and added to antibody-coated microwells. Microwells were sealed firmly 
with tape and incubated at 4°C overnight. 
The following day, wells were drained and washed four times with 1X Wash Buffer. 50ul 
detection antibody was added to each well, sealed with tape, and incubated 1h at room 
temperature. Contents were discarded and wells were washed with 1X Wash Buffer four 
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times. 50ul HRP-conjugated secondary antibody was to each well, seale with tape, and 
incubated for 30 minutes at room temperature. Contents were discarded and wells were 
washed again four times. Luminol/Enhancer solutions were mixed 1:1, and 50ul was added 
to each well. Chemiluminescence was read under RLU mode in the Hewlett-Packard 
SpectraMax Plate Reader at 425nM within 1-10 minutes of addition of substrate. 
Immunoblotting of IR auto-phosphorylation 
CHO-IR cells were seeded in 24-well plates and grown in Ham’s F-12, 10% FBS medium 
to >80% confluent (in ~48 hours). The cells are starved in Ham’s F-12 medium without FBS 
for two hours prior to experiment. 
For agonistic studies, cells were incubated in fresh Ham’s F-12 without FBS (negative 
control and baseline for normalization) or the same medium with 50nM insulin (positive 
control and 100% activity for normalization). Experimental wells were incubated in the 
same medium containing various concentrations of peptide (typically 1uM, 10uM, and 
100uM). All cells were incubated at 37C for 15 min or 30 min. 
For antagonistic studies, the experiment could be done with or without pre-treatment with 
peptides. In the case without, cells were incubated in fresh Ham’s F-12 without FBS 
(negative control and baseline for normalization) or the same medium with 50nM insulin 
(positive control and 100% activity for normalization). Experimental wells were incubated 
in the same medium containing various concentrations of peptide (typically 1uM, 10uM, 
and 100uM) AND 50 nM insulin. All cells were incubated at 37C for 15 min. In the case with 
pre-treatment, experimental wells are pre-incubated with various concentration of peptide 
(typically 1uM, 10uM, and 100uM) at 37C for 30 min before insulin (final concentration 
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50nM) was added. In the case with pre-treatment, all is the same except the experimental 
groups were pre-incubated with peptide for 30 min before the addition of insulin.  
At the end of incubation all medium is removed and cells are washed once with ice-cold PBS. 
The cells will remain on ice from this point on. Ice-cold lysis buffer is added (50-100uL/well 
for 24-well plates). 
Composition of lysis buffer: 
-SDS loading buffer, from 4X stock (To make 10 mL of 4x stock: 2.0 ml 1M Tris-HCl pH 6.8, 
0.8 g SDS, 4.0 ml 100% glycerol, 0.4 ml 14.7 M β-mercaptoethanol, 1.0 ml 0.5 M EDTA, 8 mg 
bromophenol Blue; sonicate to dissolve) 
-PMSF, 1uM, from 100X stock in ethanol 
-Protease inhibitor 1 and phosphatase inhibitors 2 & 3 from Sigma Aldrich, all from 100X 
-5% beta-mercaptoethanol 
-Fill up volume to 1X with TBS, from 10X stock, Mediatech 
(PMSF, protease inhibitors, and BME were added right before experiment) 
Cells are lysed in wells for greater than 5 minutes then collected by cell scrapers or scraping 
gently with pipet tips. The lysates were boiled for 15 minutes. They could be directly loaded 
onto SDS-PAGE gel or stored at -80°C. 
Western Blot: 
SDS-PAGE gel is transferred to nitrocellulose or PVDF membrane (PVDF must be primed 
with methanol before use) for 100 min at 33V in the cold room. 
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The membrane is washed briefly in TBS-T (1X TBS, 0.1% Tween-20) and incubated in 
blocking buffer (5% BSA in TBS-T, filtered) for 1h at room temperature. 
The membrane is washed 2X and incubated with primary antibody (Phospho-IGF-I 
Receptor β (Tyr1135/1136)/Insulin Receptor β (Tyr1150/1151) (19H7) Rabbit mAb Cell 
Signaling #3024), 1:300 in 3% BSA in TBS-T) overnight at 4C. 
The membrane is washed four times, 5-10 minutes each in TBS-T, then incubated with 
secondary antibody (Anti-rabbit IgG, HRP-linked Antibody Cell Signaling #7074) 1:3000 in 
3% BSA in TBS-T) for 1h at room temperature. The membrane was washed four times for 5-
10 min. The chemiluminescence is developed by applying a mixture of Pico-level substrate 
and 1% Femto-level substrate (Thermo) to the blot.  
Subsequently, the blot can be stripped and reblot for total IR (Insulin Receptor β (4B8) 
Rabbit mAb Cell Signaling #3025) in the same manner.  
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Chapter IV – Evaluation of Active SIRB Peptides: Binding Site, 
Specificity, and Potency Optimization 
 
Substantiating the Structural Model with Indirect Evidence 
At the end of the previous chapter, we have arrived at the hypothesis that SIRB peptides, 
much like S371 from which they are derived, not only mimic αCT of IR in sequence 
composition and helical structure, but also adheres to the same site –the hydrophobic patch 
of L1 β-sheets as the native αCT does. In order to unequivocally prove this model we would 
need to solve the structure of IR in complex with one of the active peptides, an effort that is 
currently underway. In the meantime, biochemical methods that add to the body of 
evidence that is internally consistent and collectively support the hypothesis are necessary 
efforts.  
The question of how to gather such clues is not unprecedented in the field of insulin and IR 
research. On the contrary, this is exactly a hot area of study where the much coveted 
structure of ligand-bound receptor remains elusive, albeit not due to lack of attempts. 
Besides the fact that the insulin receptor itself is an incredibly challenging subject to 
express and purify1-5, let alone crystalize (structure of the full ectodomain was not complete 
until 2011 at the cost of over a thousand liters of mammalian cell culture in a bio-reactor), 
its interaction with insulin is of such peculiar nature that further obstructs the production 
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of a co-crystal. In the last chapter there was a brief introduction of the two-site model 
speculated for insulin binding to the IR6-8. Each protomer of the IR homodimer purportedly 
contains two insulin-binding sites (hereafter referred to as sites 1 and 2 on one protomer 
and sites 1’ and 2’ on the other) that differ in affinity (figure 3.1). Binding of ligand to the 
low-affinity site (site 2) of one protomer is speculated to be followed by crosslinking of the 
half-bound ligand to the alternate site of the other protomer (site 1’). These additional 
contacts result in the experimentally observed high-affinity binding component, while 
simultaneous binding of another molecule of ligand to an unoccupied single site constitutes 
the experimentally observed low-affinity component. The first insulin molecule binds with 
high affinity by crosslinking sites 1 and 2’. On partial dissociation of the first bound ligand, a 
second molecule of insulin can crosslink the remaining the remaining sites 1’ and 2, causing 
complete dissociation of the first bound insulin. Most significantly, negative cooperativity 
results from accelerated dissociation of the first bound ligand. 
We look at what researchers have done in the absence of a structure to provide insight to 
the binding event that has built the two-site model. Physical evidence of the two sites 
themselves has come in three forms. First, alanine scan identified residues on the receptor 
that are hotspots of insulin binding9,10. Second, photo-activated crosslinking experiments 
covalently linked photoactive amino acid-substituted sites on insulin to residues on the 
receptor11-14. Importantly, residues implicated in both types of experiments overlap to a 
great degree, and locate primarily in the domains of IR discussed above, providing further 
confidence on the validity of binding sites. A third and final line of evidence is none other 
than the case in point – the phage display study that yielded IR-binding peptides, they are 
grouped into two classes that bind to distinct sites on the IR according to results from 
mutual competition assays. Although no physical data of where exactly on the receptor 
these peptide bind has been reported, it is strongly believed that they individually bind to 
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one of the two sites that insulin touches. And this last hypothesis is incidentally what we 
would like to prove. Interesting enough, both of the first two studies, alanine scan and 
photo-activated crosslinking done on the insulin-IR system can in theory be applied to the 
peptide-IR system as well.  
A successful study of alanine scan, as the name suggests, demands a thorough screening of 
all residues on the receptor suspected to be hotspots, and in this context with multiple-
component binding sites means a large of number of mutants to be made. We have made 
the point of limited accessibility of recombinant IR (let aside production of many mutants). 
Photo-activated cross-linking, on the other hand, requires no perturbation on the protein 
but chemical modification on the peptide only. Therefore, we selected this methodology as a 
starting point.  
 
 
Figure 4.1. Use of photo-activated cross-linking (PCL) as a means to reveal binding site of 
a ligand’s binding site on target protein. (A) Benzoylphenylalanine (BPA), the photo-active 
probe incorporated into the ligand. (B) Schematic representation of cross-linking between BPA 
and protein via formation of new C-C bond. (C) Reaction mechanism of PCL. 
 77 
 
Attempts at Photo-activated Cross-linking of SIRB Peptide to IR 
Photo-activated cross-linking (PCL) has proved a powerful technique for probing molecular 
interactions15,16. The assay involves installment of non-natural amino acids containing 
various UV-responsive functional groups on a ligand that can form covalent bonds with the 
ligand’s binding target when irradiated at the proper wavelength. The covalently linked 
complex is then subjected to limited proteolysis, after which the fragments can be visualized 
on SDS-PAGE. Oftentimes this is enough to reveal roughly where on the protein the cross-
linking reaction has taken place; alternatively, the band containing the ligand is excised to 
be analyzed on LC-LC/MS and the exact residue on the target that is cross-linked can be 
identified. Although the assay has the advantage being volatile enough to adapt to almost 
any binding system, there are also pitfalls that could lower its success rate, such as 
inefficient bond formation due to low affinity, nonspecific binding and cross-linking, 
heterogeneity of the covalently linked complex that clouds subsequent analytical chemistry, 
etc.   
A variety of photo-active probes, such as para-benzoyl-phenylalanine (BPA), para-azido-
phenylalanine (PAP), and azetidine-based amino acids exist in the toolbox of PCL. Previous 
studies of the insulin: IR system have found use of both BPA17,18_ENREF_3 and PAP14,19, 
which were substituted into a handful of residues on insulin to react with IR and yielded the 
important information discussed earlier.  To us, these two molecules showed similar 
promises in working, and we chose the slightly more hydrophobic BPA to go forth for the 
consideration that the speculated binding site on the receptor contains a greasy patch. The 
reaction mechanism of BPA and a C-H bond on a protein under photo-activation and the 
resulting C-C bond formation is depicted by figure 4.1. 
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The hypothesis for our photoaffinity labeling experiment was simple: if S371 or any SIRB 
peptide binds to the IR consistently at a defined site (and that site is where we think it is, i.e. 
insulin-binding Site 1 on the receptor), then a version of the peptide derivatized with a 
photo-active probe should cross-link to that site upon UV irradiation on the pre-formed 
complex. Ensuing analytics would allow us to pinpoint the residue(s) on the IR. In execution, 
however, positioning of the photo-active amino acid on the peptide was not immediately 
obvious. On one hand, it needs to be physically close enough to the protein to react with it; 
on the other, it inevitably brings perturbation to the canonical binding interface that may or 
may not diminish binding and thus defeat the purpose. Because there was little information 
other than guesswork to help on decision-making, we had to empirically explore a variety of 
options. 
As such we were again facing the need of a large synthetic project to produce the photo-
active peptides, which called for narrowing down of choice of the model peptide at least. 
From previous screening of the SIRB library, the most potent peptide in terms of activity on 
the IR (antagonistic) is SIRB-B5. We reasoned that its high potency and low IC50 of IR and 
Akt1 phosphorylation compared to the rest of the library may arise from a higher affinity to 
the receptor, and therefore used its composition as a basis for making compounds for PCL. 
Figure 4.2. Incorporation of BPA into SIRB-B5. BPA was placed at either the N-terminus (SIRB-
B5-BPA0) or embedded in the sequence of SIRB-B5 (SIRB-B5-BPA1-6). In the latter case, BPA 
replaced residues that were hypothesized to directly interact with L1 based on the structural 
model. 
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SIRB-B5 is from the i, i+7series, containing two non-natural amino acids used for stapling 
and leaving 14 other residues as well as the termini for possible sites of BPA substitution. 
Figure 4.2 summarizes the list of photo-active peptides designed for synthesis, termed the 
“SIRB-B5-BPA” series. BPA0 features the probe dangling off the N-terminus of the peptide 
and separated from the primary sequence by a β-Alanine linker, so as to introduce as little 
disruption to the original protein-protein interactions as possible. In BPA1-6, the probe is 
used to directly replace each of the residues at the hypothetical binding interface that 
actively contribute to binding via hydrophobic or electrostatic interactions (see chapter III). 
The hope here is that these are the “branches” that reach out farthest and closest to the 
protein, and should be the most promising in compensating for the apparently low binding 
affinity as suggested by a meek IC50.  
Incorporation of BPA was quite straightforward, since Fmoc-BPA is commercially available 
and could basically be treated as a normal amino acid in the SPPS process (discussed in 
more detail in Experimental Methods). Biotin was added to the N-terminus of each peptide 
as a handle for pull-down or Western visualization. All seven peptides were successfully 
made and purified, but an alarming sign lit up as the final products were analyzed on LC/MS. 
Retention times of all SIRB peptides had been noted in the past to be on the long end and 
significantly longer than the wild-type peptide S371, plausibly a reflection of the 
hydrophobicity added by the staples (Series A, ones with the shortest and least greasy 
cross-link, fared better than the rest). Consequently, the aqueous solubility of the peptides 
was not impressive, but high enough to allow for experimentation being done in buffers 
such as PBS or cell culture media. Now with the BPA substitution the retention time climbed 
to a record high; some of these peptides did not elute from the C18 column until the solvent 
reached over 90% acetonitrile. We had but to accept the physical properties of the peptide 
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as they were which goes to show the intrinsic limits of the grand scheme of this 
investigation. 
The other component of the bimolecular photo-activated reaction was the receptor. Prior to 
this point we had circumvented the necessity of recombinantly expressed insulin receptor, 
as cell-based assays served the purpose of screening the library. In order to visualize the 
Figure 4.3. IR ectodomain constructs. (A) Truncation or deletion of the IR 
ectodomain that have been reported to retain high affinity for insulin will be 
investigated in this work. Constructs with or without -CT will be used for 
crystallization and binding assays in the future with SIRB peptides in parallel 
to examine whether α-CT affects the interaction of SIRB peptides with the IR. 
(B) Expression of IR constructs. HEK293 cells were stably transfected with 
various constructs; protein secreted into expression medium could be 
visualized by Western blot of their His5 tag. 
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cross-linked product on SDS-PAGE or conduct downstream mass spectrometry analysis, we 
had to have available a reasonable amount of some form of IR ectodomain in a cell-free 
system. In collaboration with Dr. Minyun Zhou, a post-doctoral fellow in the lab, we 
designed three constructs of IR that differed in length (Figure 4.3A).  
The first construct included the first three domains only and was thus termed “L1-CR-L2”. 
This particular truncation of the α-subunit brought about the first ever crystal structure of 
IR4 and, interestingly, of the type I insulin-like growth factor receptor (IGF1R)20 before as 
well (no complete structure of the ectodomain of IGF1R has yet been solved to date). 
Referred-to as the mini-receptor or IR485 (for number of residues included), the well-
studied contruct was generally thought to be easier to express, purify, and handle than any 
other selection of domains2,3. By itself L1-CR-L2 does not bind to insulin, another line of 
evidence the ligand-binding requires multiple components of the IR, some of which in other 
domains. When the α-CT segment (residues 704-719) was fused to the C-terminus of the 
constructs, insulin binding was reconstituted to nanomolar affinity, but no negative 
cooperativity characteristic of native receptor-ligand interaction was observed. Most 
strikingly, even the inclusion of free α-CT peptide in solution could restore the insulin-
binding ability of L1-CR-L2 to a similar degree. It is remarkable how much insight on the 
composition of binding sites had been provided by this minimized receptor. When the long 
circulating belief that the β-sheets of L1 and α-CT are interaction partners in trans was 
finally proved by crystallographic data in 2010, researchers obtained another interesting 
result along the way5. Again they made use of the mini-receptor by measuring its binding 
affinity to the wild-type α-CT peptide and to a double mutant of α-CT on which they had 
substituted two residues from S371 predicted to be important for binding.  They found that 
the Kd of the double mutant to the mini-receptor was over a thousand-fold lower than that 
of wild-type α-CT. Of significance was not just that a change based on phage display results 
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outcompeted the naturally evolved sequence (of course, one can argue that the natural α-CT 
might have evolved purposely NOT to be too tight a binder to L1 so as to wriggle around 
when insulin comes in. This was later proven to be the case; more will be discussed later), 
but that this was in support of the hypothesis of S371 being a structural mimic of α-CT. The 
corollary of the hypothesis would be the residues evolved to be important for S371’s 
binding the receptor would exert similar increase in affinity when grafted to α-CT, the exact 
observation here. Combining all prior knowledge, the mini-receptor lacking native α-CT was 
the ideal construct for binding assays with SIRB peptides.  
The other two constructs, mIR.Fn1 and mIR.Fn1-Ex10, both contain α-CT and most of the 
other domains of the α-subunit, and were expected to have lower affinity to SIRB peptides. 
mIR.Fn1 was found to bind to insulin with high affinity. mIR.Fn1-Ex10 in particular was the 
only incomplete combination of α-subunit domains that exhibited insulin-binding behavior 
identical to that of the whole ectodomain, both in terms of affinity and negative 
cooperativity. We envisioned that having these versions of IR which retain the natural 
ligand binding activity in addition to the mini-receptor would be necessary as a reality 
check. 
All three constructs were cloned in PCDNA 3.1 expression vector with His6 and Myc tags for 
purification, and transfected in HEK 293 cells to generate single-colony stable cell lines that 
produced and secreted the protein into expression medium. Identity of each protein was 
confirmed by Western blot with anti-His-tag HRP-conjugated antibody (figure 4.3B). L1-CR-
L2 achieved the highest expression level of all three constructs, as expected.  
Purification of the protein would require a large scale of input, which took considerable 
time and effort to generate because of limitations of the mammalian expression system. 
Before the availability of pure protein, we wanted a head start on the PCL experiment with 
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the expression media containing sparse but Western blot-visible amounts of protein. The 
assay setup is shown in figure 4.4A. 
In this assay we ran into multiple obstacles. First, the aqueous solubility of BPA peptides 
turned out to be very low indeed – the highest concentration that they could be dissolved in 
the expression medium without precipitating was about 100μM. Such property was 
definitely against the need of having SIRB-BPA at high concentration and excess over the 
protein in solution to drive the complex formation and cross-linking to higher degree of 
completion.  Second, both the efficiency and specificity of PCL were unacceptably low, 
manifested in smeary Western blots where a faint band of the correctly sized protein (L1-
CR-L2, ~70kDa) was barely distinguishable from background (figure 4.4B). Through 
repeated modification of conditions and troubleshooting, the best result remained the one 
shown and was generated by SIRB-BPA0. With the other peptides we saw no cross-linked 
product whatsoever.  
The PCL experiment lacked a good positive control (ideally a BPA-labeled insulin would be 
the gold standard, but synthesis of such a compound would be a project in its own right), 
Figure 4.4. Photo-activated cross-linking of SIRB-B5-BPA and L1-CR-L2. (A) Schematic 
representation of PCL experiment. Biotinylated SIRB-B5-BPA allows for detection of product by 
Western blot. (B) Representative result (SIRB-B5-BPA0) showing lack of robustness and 
specificity of PCL reaction. 
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and made it hard to diagnose where 
things went wrong: complex not 
forming? Photochemistry not 
happening? Light source not strong 
enough? To answer at least the first 
question, all seven SIRB-B5-BPA 
peptides were tested in the IR 
phosphorylation assay (see previous 
chapter). The result was as 
disappointing as it was illuminating: 
peptides BPA1-6 all significantly lost 
their antagonist activity to reduce insulin signaling (figure 4.5); that they would not cross-
link with the receptor efficiently was hardly a surprise any longer. A likely culprit for this 
observed loss-of-function was, as mentioned earlier, the perturbation of the binding 
interface by the probe BPA. We noted that SIRB-B5-BPA0, the peptide with the probe at the 
N-terminus and no change in the primary sequence, did preserve the antagonist effect 
comparable to the original SIRB-B5, agreeing with the suspected explanation. Unfortunately 
as stated, even this peptide could not cross-link to any of the three constructs in a clean and 
satisfactory fashion, possibly because of the probe’s distant location from the interface. The 
Western blot quality was not good enough for a concentrated sample to be collected by SDS-
PAGE excision as planned.  
At this point, it was clear we needed a different approach to probe the binding site of SIRB. 
We could launch another synthetic expedition to make more variations of the BPA peptide, 
or adapt other types of photo-active probe. However, the return on investment of such 
Figure 4.5. Loss of function of SIRB-B5 BPA 
peptides. Effects of SIRB peptides on Phospho-IR 
level detected by western blot. CHO-IR cells were 
treated with 10 µM peptides in the presence of 50 nM 
insulin. Antagonist effect of the original SIRB-B5 was 
lost in most BPA peptides. 
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endeavors was questionable since they suffered from the same trial-and-error base and lack 
of predictability as the previous attempt.  
Despite the set-back of PCL, successful production of the three IR constructs lit up the hope 
for alternative means to the same end. The path we took was affinity pull-down and 
competition as described in the next section. 
 
Pull-down of IR by SIRB-B5 and Competition with α-CT peptides 
We took a step back and asked the question of how to establish the basic event of binding, 
which so far had not been supported by direct physical evidence. With the recombinant 
protein at hand, conditions were now fully permissible for an affinity pull-down. We remade 
active SIRB hits, including B5, to install biotin at their N-termini after a β-Alanine linker 
(referred-to as “Bio-SIRB”). Figure 4.6A depicts the experimental design of the pull-down. 
The biotinylated peptide could be immobilized on streptavidin-coated beads and pull down 
the protein. Here again the penta-His tag on the receptor made visualization very 
straightforward. 
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After optimization of bead choice and binding/wash conditions, we could observe 
reproducible pull-down of two IR constructs, L1-CR-L2 and mIR.Fn0-Ex10 by Bio-SIRB-B5. 
We were confident of the specificity of binding because of 1% BSA in the binding buffer and 
use of a similarly-sized negative control protein that was not pulled down. Results are 
shown in figure 4.6B and 4.6C. Although both constructs of IR bind to Bio-SIRB-B5, L1-CR-
L2 definitely does so with higher affinity, evident in higher intensity of the bands. This 
difference in binding affinity was as we had expected because mIR.Fn0-Ex10, unlike L1-CR-
L2 , contained its native α-CT segment that could compete with SIRB-B5. 
In addition to the basic pull-down of IR by SIRB, we would like to further corroborate the 
assay by competition with insulin. As mentioned, L1-CR-L2 loses ligand binding but 
mIR.Fn0-Ex10 should retain full affinity to insulin as the wild-type receptor. Therefore, 
titration of insulin into the complex mixture should abolish SIRB-B5 pull-down of mIR.Fn0-
Ex10 at some point of concentration and have no effect on L1-CR-L2. Such indeed was the 
Figure 4.6. Affinity pull-down of IR by SIRB-B5. (A) Schematic representation of 
the pull-down assay: Biotinylated SIRB-B5 could be immobilized on streptavidin-
coated beads and pull down IR from expression medium. Precipitated protein could 
be visualized by Western blot of His5 tag. (B) L1-CR-L2 pulled down by SIRB-B5. (C) 
mIR-Fn1-Ex10 pulled down by SIRB-B5 and competition by insulin. 
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Figure 4.7. Design of competition pull-down to probe the binding site of SIRB-B5. (A) 
Sequences of competitive peptides: wild-type αCT, gain-of-function double mutant, and loss-of-
function mutants as negative controls. (B) Schematic representation of competitive pull-down. 
(C) Close-up view of interaction between αCT (purple) and L1 β-sheets (blue). The two 
phenylalanine residues on αCT were chosen to mutate in negative control peptides. 
observation (figure 4.6C). We have now gained additional confidence on the validity of the 
pull-down assay and established the basis of the key experiment for probing the binding 
site of SIRB: α-CT competition. The rationale of the experiment was that since α-CT binds to 
the L1 domain in trans is a known fact backed by both structural data biochemical studies, 
we could provide evidence for SIRB peptides’ binding being at the same site by competing 
the peptide’s pull-down of L1-CR-L2 with addition of free α-CT. The attractiveness of this 
experiment did not stop at its simplicity, but also the existence of perfect controls. We have 
described the double mutant (R701Y/T703W) and its increase in binding affinity to the 
mini-receptor earlier; this peptide could be used as a gain-of-function positive control in the 
experiment, i.e. a more potent competitor than the wild-type peptide. To the other end, we 
would like to include a loss-of-function negative mutant as well. Revisiting the structure, we 
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selected the F711 and F715, two residues appear to be the most important in α-CT’s binding 
to L1 and conserved in both IGF1R α-CT and the S371 sequence to mutate to either Ala or 
other disruptive residues. The peptides are summarized in figure 4.7. 
As conditions of the pull-down had been optimized, we arrived at desired results at ease in 
the competition assay (figure 4.8.). First, negative mutants were screened, and all three 
mutants expectedly did not affect pull-down of L1-CR-L2 by Bio-SIRB-B5. Then α-CT_wt, α-
CT_dm, and α-CT_nm1 were all titrated to the binding mixture over a range of 
concentrations and the results compared side-by-side. While the α-CT_nm1 did not 
decrease the amount of protein pulled down even at the highest concentration of 100μM, 
both α-CT_wt and α-CT_dm showed 
competition with the binding event in 
a dose-dependent manner. 
Remarkably, α-CT_dm outdid its 
wild-type counterpart in the 
competition assay by almost three 
orders of magnitude of concentration, 
quite in agreement with the its 
reported Kd with the mini-receptor. 
Barring potential allosteric changes 
in the receptor dimer in situ that 
were not accounted for by the 
truncated construct, these results 
would suggest that SIRB-B5 compete 
with α-CT for binding to the receptor, 
 
Figure 4.8. Results of competitive pull-down assay. 
L1-CR-L2 was pulled down by SIRB-B5 alone or in the 
presence of competitive peptides. (A) Concentration 
range of αCTnm, αCTwt, and αCTdm was 10, 50, and 
100 µM. (B) Concentration range of αCTnm and αCTwt 
was the same as in (A), while concentration range of 
αCTdm was decreased to 0.1, 1, and 10 µM. 
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and therefore share the same binding site, i.e. the β-sheets of L1 domain. 
In summary, the pull-down assay and competition with α-CT derived peptides provided 
indirect but concrete evidence for localization of SIRB peptides on the insulin receptor. 
Efforts are currently underway for obtaining structural data of the bound complex that 
would put the nail in the coffin.  
 
SIRB-B5’s Effect on IGF-1R 
In Chapter III we investigated the effects of SIRB peptides on IR signaling, and were able to 
establish the on-target activity by virtue of a CHO cell line that expressed IR in large 
quantities but no related receptor tyrosine kinases (RTKs). However, such experiments 
have not ruled out possible off-target effects. Particularly of relevance is the type-1 insulin-
like growth factor receptor (IGF-1R) of the IR subfamily. 
IR and IGF-1R share identical gene structure and domain organizations with the exception 
of exon 11, which is present in the IR gene but not IGF1R. Exon 11, a 12-amino acid segment 
close to the C-terminus of the α-subunit, is included in one isoform of IR, IR-B, and absent in 
the other, IR-A. Therefore, IR-A is structurally more similar to IGF-1R and has a higher 
affinity to IGF-1 and IGF-2 than IR-B. Like IGF1R, IR-A is also implicated in many types of 
cancer. Excluding Exon 11, both isoforms of IR have high sequence similarity with IGF-1R, 
varying from 41% to 84% depending on the domain. Moreover, monomers of IR and IGF1R 
have been observed to form hybrid receptors both naturally in tissues and in tumors that 
express more than one member of the subfamily. Other functionally related RTKs, such as 
the epidermal growth factor receptor (EGFR) subfamily, have certain domains in common 
with IR and IGF-1R, but the overall structural homology does not come close1,4,8,20,21.  
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Given such evolutionary relationships and close ties, we would expect ligand-binding and 
signaling pathway of the IR and IGF1R to be just as promiscuous and interweaving, which is 
indeed the case. Insulin and IGF-1 can both bind to IR and IGF-1R in a competitive manner. 
The binding affinity of ligand to non-canonical receptor is lower, but not by much: insulin 
and IGF-1 bind to their canonical receptor with Kd in the range of 1-2x10-10 M, and to the 
other receptor with Kd in the range of 1-2x10-8 M22.  
All evidence suggest that S371 and SIRB peptides should bind to IGF-1R and exert similar 
effects on signaling, if they are indeed a partial mimic of insulin and occupy one of the 
multicomponent sites insulin does on both IR and IGF-1R. In fact, if we looked a bit closer at 
the sequence and structure of IGF-1R in both its L1 and α-CT domains, we found that the 
above statement is almost a corollary of the purported binding model of these peptides and 
has to be true. First, crystal structure encompassing the L1 domain exists for both IR and 
 
Figure 4.9. Comparison of Site 1 between IR and IGF-1R. (A) Sequence similarity of the β-sheets 
of L1 and αCT between IR and IGF-1R. (B) Overlay of X-ray structure coordinates of IR (cyan) and 
IGF-1R (purple). 
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IGF-1R, an overlay of which showed the almost identical conformations of the β-sheets 
(figure 4.9). Sequence homology of this particular segment in L1 reaches as high as 85% 
between the two receptors. Furthermore, if we focused on only the residues that interact 
with α-CT (based on the IR crystal structure for IGF-1R’s was cut off after the first three 
domains), we found all but one out of 11 amino acids to be identical. The one non-
homologous site is Phe vs. Tyr, still quite conserved from a structural point-of-view. Second, 
we examined the α-CT of the two receptors. Although the crystal structure of IGF-1R does 
not include its α-CT, we could take a cue from the sequence alignment with IR α-CT that 
shows a high degree of similarity too. All the L1-interacting residues are the same except for 
IR F701/Y708 and IGF-1R Y701/F708, similarly “non-different” as in the case of L1.  
Besides the analysis above, we would to confirm by experiment that SIRB peptides interact 
with IGF-1R in a way similar to IR. The concept is quite simple – we needed to get the same 
kind of measurement of signaling effects on IGF-1R, i.e. Western blot or ELISA of its 
phosphorylation levels, but in practice the high similarity between the two receptors 
complicates matters. The antibody that recognizes the phosphorylated form of the receptor 
cannot distinguish between IR and IGF-1R. Earlier, we were able to study phospho-IR 
specifically thanks to the CHO-IR cell line that expressed no IGF-1R. We could try to produce 
a similar stable cell line expressing IGF-1R in high quantities exclusively. Alternatively, a 
less time-consuming route was to immuno-precipitate IGF-1R with the total IGF-1R 
antibody, which does discriminate against IR, before blotting for phosphorylation, as has 
been successfully used in a number of studies. 
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HepG2 cells which have endogenous 
expression of both IR and IGF-1R at 
relatively high levels were chosen to do 
the experiment. We tested the 
antagonist effect of SIRB-B5, which had 
previously been thoroughly 
characterized on IR, on IGF-1R, with 
results shown in figure 4.10. Not 
surprisingly, SIRB-B5 demonstrates 
similar antagonist activity on IGF-1R, 
reducing its phosphorylation by IGF-1 
in a dose-dependent fashion.  
What are the implications of SIRB’s lack of selectivity for IR vs. IGF-1R? From a therapeutic 
standpoint, one can argue for both the pros and cons: it renders the compounds less 
attractive as IR agonists used for diabetes (a lot of work needs to be done on improving the 
potency of agonists anyway), but raises the luring prospect of the antagonists’ potential in 
cancer treatment as they can inhibit IGF-1R. From this dissertation’s point of view, the 
result agreed nicely with the earlier section on the structural model of the peptides’ binding 
to both receptors, and hence holds much appreciated value. 
 
 
 
 
Figure 4.10. SIRB-B5 antagonism on IGF-1R. 
HepG2 cells were treated with SIRB-B5 in the 
presence of IGF1. IGF-1R was immuno-
precipitated to be distinguished from IR on 
Phospho-IR/IGF-1R .Western blot.  
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Covalent Dimerization of SIRB to Improve Potency 
Our next attempt was to optimize SIRB hits to reach higher potency. The primary means to 
achieving this goal is dimerization, and here our reasoning was three-fold. First, Schaffer, L. 
et al. have reported use of S371 and S446, a site 2 binding peptide from the original phage 
display study as building blocks for peptide dimers23.  Both were antagonists like the rest of 
the phage display hits (other than a few of site 2 peptides that were inactive), though S371 
demonstrates weak agonistic effects at high concentrations in agreement with our 
preliminary screening results of series A and B (data not shown). Spacers of various lengths 
and different types of orientation of monomers were adapted in the synthesis to create a 
diverse set of homodimers and heterodimers. Of these, some were antagonists and others 
became agonists, including a homodimers of S371 and a heterodimer, while all had increase 
in binding affinity to the receptor ranging from 10- to 1000-fold compared to the monomers 
alone. This example clearly demonstrates the potential of producing agonistic dimers that 
presumably interact with both binding sites from antagonists that touch only one at a time. 
Second, a similar principle had been applied to other receptor tyrosine kinase systems. 
Phage display yielded peptides that could bind to and activate the erythropoietin (EPO) 
receptor but bore no sequence homology to the hormone itself24. When such peptides were 
oligomerized non-covalently, their affinity for the EPO receptor improved by 10- to 20-fold. 
Synthetic homodimerization of EMP1, the highest-affinity monomer and a weak agonist on 
its own, resulted in a 100-fold increase in affinity and an equal boost in agonistic effect of 
receptor activation in vivo. Interestingly, even an inactive peptide monomer yielded an 
agonistic homodimer25. Another noteworthy case is the discovery of a high-affinity peptide 
binder to the thrombopoietin (TPO) receptor and subsequent dimerization that gave rise to 
an agonist with a picomolar EC50, which was equipotent to the natural hormone. Here the 
gain in activity even outweighed the gain in affinity, suggesting that improved stability due 
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to structural constraints could contribute directly to higher potency. Third, as we take a 
close look at the crystal structure of IR ectodomain, the N-termini of -CT domains are quite 
close to each other (approximately 31 Å apart) across the dimer interface. Since S371 is a 
mimic of -CT, it stands to reason that such an orientation further adds to the likelihood of 
increased affinity and potency brought by dimerization of the peptide.  
In addition to the reasoning above, we noted earlier that certain SIRB peptides from the 
later series – D2, D5 and E2 – exhibited agonist activity at high concentrations (100µM or 
above). The most likely explanation was that although the peptides as monomer could not 
engage both Site 1 and Site 2 to induce conformational changes that activate the receptor, 
once their concentration is high enough for dimerization or oligomerization the non-
covalent self-assembly would be able to cross-link both sites. In the earlier series, the 
hydrocarbon staple is short; the D and E series feature staples that are lengthier and better 
Van der Waals contributors, which may favor non-covalent homodimerization of the 
peptide. If such speculation holds, then chemically dimerizing the peptides should 
effectively increase the local concentration and the potency by a long way.  
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As for the execution of dimer synthesis, we saw three dimensions on which variations are 
important for arriving at an optimal compound empirically. The first dimension is the 
choice of peptide monomers. Guided by previous examples discussed above, we would 
incorporate both homodimers and heterodimers via combination of the most active SIRB 
peptides into this new library. Secondly, there is a variety of choice for linker (e.g. PEG or 
amino acid) and conjugation method (succinimide, native chemical ligation, etc.). The most 
important attributes of linker chemistry are arguably length and rigidity, frequently 
Figure 4.11. Design of SIRB homodimer synthesis. Free amine on the N-terminus of 
SIRB could react readily with succinimide-containing entities. Self-dimerization could be 
achieved in one step using a selection of bis(succinimide) linkers varying in length of 
spacer arm.  
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interdependent (shorter spacers tend to offer less conformational freedom). The last 
dimension of permutation is the relative orientation of the peptides – N- to N-, N- to C-, etc. 
Combining all three dimensions, we could see that again a diligent and collectively 
exhaustive synthetic project would find its worth. 
While the full-blown mission has not been complete, we have made initial attempts at 
tackling the problem and getting preliminary data. We started with the most active 
antagonist, SIRB-B5, and agonist, SIRB-D2, to use as building blocks for homodimerization. 
As for linker chemistry, we chose a bis-succinimide system where the N-
hydroxysuccinimide ester ends react readily with terminal amine of the peptide to drive 
homodimerization, and the spacer in between vary in length to sample a range of flexibility 
for the resulting dimer (figure 4.11). The 
three spacers were glutaric acid (Glu), 
PEG5, and PEG9. Such a reaction scheme 
constrains the orientation to be of N- to 
N- linkage.  
After troubleshooting the conditions for 
dimer synthesis, we obtained products 
(B5)2Glu, (B5)2PEG5, (B5)2PEG9, and 
(D2)2Glu, (D2)2PEG5, (D2)2PEG9. The 
dimeric peptides were subject to activity 
profiling in the IR and Akt1 ELISA assay 
as described in Chapter III. The results 
were very encouraging (4.12). All 
showed a significant shift to lower concentration in reaching maximal effects. Curiously the 
agonistic activity on Akt1 was much stronger than seen in IR across all compounds. 
 
Figure 4.12. Increase of agonist potency by 
dimerization of SIRB-D2. CHO-IR cells were 
treated with increasing concentration of 
(D2)2Glu (1, 10, and 100 µM) in the absence of 
insulin. Results are shown in comparison of 
stimulation by 50nM insulin. Total IR levels 
were measured as control. 
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(D2)2Glu appeared to be especially active in promoting phosphorylation of both proteins. 
Western blot confirmed the increased potency of (D2)2Glu, as at 10μM the peptide dimer 
could induce as much phosphorylation as 50nM insulin. This represented a 10-fold increase 
in potency, modest but promising for future efforts. 
 
Topic Closing Remarks 
Potency Optimization 
The increase in agonist activity of SIRB-D2 homodimers compared to the monomer suggests 
that there is further room in affinity and potency improvement for current SIRB hits. 
Extensive synthesis of combinatorial homo- and heterodimers, however, must precede the 
hunt for the most active compounds, much like our earlier efforts on completing the first-
generation SIRB library. Alternatively, obtaining structural data of current compounds 
bound to IR would provide instructions on rational design of better agonists and 
antagonists. The quest for complex crystal formation is currently underway.   
In addition to dimerization of SIRB hits, there are lessons to be learned by tethering a SIRB 
peptide to the other class of peptides from the phage display study. For example, Novo 
Nordisk reported potent antagonist effects of S961, a linear combination of S371 and S661, 
a Site 2 peptide. In our IR phosphorylation assay, the potency of S961 was almost 1000 fold 
stronger than SIRB-B5. This prompts us to wonder what would happen if we extended the 
sequence of SIRB-B5 to include the Site 2 peptide. In other words, create a stapled version 
of S961. We imagine the resulting compound to retain if not exhibit even higher potency 
while having the advantage on pharmacokinetic properties from the staple. 
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Integrating New Structural Information of Partial Ligand Binding State 
Recent structures of insulin in complex with IR truncations further elucidate how insulin 
engages its primary binding site via CT.  It has been revealed that with respect to its 
counterpart in apo-form IR, CT is displaced on the L1 surface and C-terminally extended in 
IR-insulin complex(Figure 4.13.).  Both structural and biochemical data show that the N-
terminal CT favors “antagonist conformation” without insulin binding, while C-terminal 
portion adopts “agonist conformation” in the presence of insulin.  
As N-terminal αCT is the major 
determinant for L1 interactions and 
only C-terminal αCT is involved in 
insulin binding, it is reasonable to 
design the stapled insulin sensitizers 
based on C-terminus of αCT.  
Although these peptides cannot bind 
to IR by themselves, in the presence 
of insulin, they will exhibit high affinity for IR.  Considering the C-terminal αCT is short (6 
residues only), it allows us to introduce different elements that can either engage or block 
the insulin binding to the site 2 on IR and thus increase or decrease the insulin affinity for IR.   
 
 
 
 
 
Figure 4.13. Change in position of -CT during 
insulin binding. (A) -CT (purple, 705-715) in 
insulin-IR complex. (B) -CT (red, 693-715) in 
insulin-free IR. 
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Experimental Methods 
Synthesis of BPA-containing Peptides 
SIRB-BPA peptides were synthesized using the standard Fmoc-SPPS method as described in 
Chapter I. BPA (EMD Chemicals) was treated as a “natural” amino acid and was 
incorporated using an amount of 3 molar equivalents to resin.  
 
Cloning and Expression of IR Ectodomain Constructs 
Full-length insulin receptor cDNA was a generous gift from Professor Joseph Bass at 
Northwestern University. Different truncations of the IR ectodomain, as shown in figure 4.3, 
were cloned into a PCDNA3.1hygro+ vector (Life Technology) using the following primers: 
1) mIR-Fn1-Ex10 
D2_P2_r: cagcttcagccc TGGATCCAGGGGCACAGAG 
D2_P3_f: CCCCTGGATCCA gggctgaagctgccctcgag 
2) mIR-Fn1 
D3_P2_r: gtaatcctcaaacgt TGCCGA GGTGGCATCTGTCTGGACATAAATG 
D3_P3_f: GACAGATGCCACC TCGGCA acgtttgaggattacctgcacaac 
3) L1-CR-L2 
D4_P2_r: gtaatcctcaaacgt CGATCC AAGTAACTCATTTTCACAGGATGCCTG 
D4_P3_f: CTGTGAAAATGAGTTACTT GGATCG acgtttgaggattacctgcacaac 
 
Resulting plasmids were transformed into DH5α competent cells and selected by ampicillin. 
Maxi-prepped plasmids were used to transfect HEK 293S cells using the JetPrime kit. Stably 
transfected cell line was generated for each protein by treatment of hygromycin for a week. 
Furthermore, single colony was picked from each stable cell line by dilution of original 
culture into to fresh expression medium and grown in 96-well plate, at a concentration such 
that each well would on average contain a single cell.  
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Expressed protein was harvested by collecting expression medium and centrifugation to 
remove cell debris. Expression medium was flash frozen and stored in aliquots at -20°C 
until use. 
 
Pull-down Assay of IR and SIRB-B5 
Preparation: Life Technology M280 magnetic streptavidin-coated beads were equilibrated 
in Binding Buffer and drained using the magnetic strip. Biotinylated peptides dissolved in 
Binding Buffer at 10µM were added to the beads, along with one sample treated with DMSO 
control in Binding Buffer. Immobilization of peptides was done by gentle nutating overnight 
in the cold room. IR construct (L1-CR-L2 or mIR_Fn1-Fn0) from expression medium was 
dialyzed into 1X phosphate buffered saline in the cold room overnight. 
Pull-down without competition: on the next day, the beads were drained and washed 
thoroughly in Wash Buffer. 0.5% BSA was added to protein solution (PBS), and the solution 
was introduced to the peptide-bound or mock beads. Pull-down was allowed to go for up to 
3h by gentle nutating in the cold room. All samples were then drained and washed 
extensively in Wash Buffer (either low salt or high salt). At the end of the last wash, 1X SDS 
Loading Buffer was added to the beads and the mixture was boiled at 95°C for at least 5 
minutes to release bound protein. Samples were then run on SDS-PAGE gel to be visualized 
by Western blot. 
Immunoblotting: At the completion of gel electrophoresis, SDS-PAGE was transferred to 
nitrocellulose membrane using the wet transfer method in Transfer Buffer. After transfer, 
the blot was blocked in Blocking Buffer (Qiagen) for up to 1h at room temperature, and 
incubated with anti-His5 antibody (Qiagen) at 1:1000 in Blocking Buffer overnight in the 
cold room. On the next day, the blot was washed extensively in tris-buffered saline, 0.1% 
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Tween-20 before visualization by addition of SuperSignal West Pico Chemiluminescent 
Substrate from Pierce. 
Pull-down with Competition: the same protocol was used, with the exception that after 
dialysis of IR L1-CR-L2 and before addition of the protein to bead-bound peptides, the 
protein was incubated with indicated concentration of peptides for 1h at 4°C to allow 
binding. 
Binding Buffer 
Phosphate Buffered Saline pH 7.4 (NaCl = 147mM, low salt) 
0.01%(v/v) Tween-20 
0.5%(w/v) BSA  
 
Wash Buffer 
Phosphate Buffered Saline pH 7.4 (NaCl = 147mM, low salt) 
0.01%(v/v) Tween-20 
Phosphate Buffered Saline pH 7.4 (NaCl = 500mM, high salt) 
0.01%(v/v) Tween-20 
 
 
 
Immunoprecipitation of IGF-1R 
HepG2 cells grown to 80% confluent in 10cm plates or 6-well plates were serum-starved in 
DMEM (penicillin/streptomycin added) overnight. On the next day, the following solutions 
were prepared: 50nM IGF-1 in complete growth medium (from 50µM stock, a gift from 
Professor Douglas Melton’s group), 10µM or 100µM peptide in complete growth medium 
(from 10mM DMSO stock), and vehicle (the highest concentration of DMSO used in peptide 
samples).  Old media was removed and cells were treated with appropriate compounds. The 
vehicle was used to create baseline, and the 50nM IGF-1 solution was used to give maximal 
amount of signal (100% phosphorylation). SIRB-B5 was given in combination with 50nM 
IGF-1. Cells were incubated at 37°C under 5% CO2 for 15 minutes. 
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At the end of treatment, media was aspirated and cells were washed with ice cold PBS, and 
subsequently lysed using Lysis Buffer (from 10X Lysis Buffer, Cell Signaling, 1mM PMSF 
added prior to use). Cells were incubated in Lysis Buffer plates/wells in the cold room with 
gentle rocking for 10 min, then subjected to quick sonication. The cell lysate was then 
centrifuged at 12,000rpm for 10 min in the cold room. The clarified lysate was collected and 
aliquots were flash frozen in liquid nitrogen and stored at -80°C until use.  
Immunoprecipitation: Clarified lysate was first quantified by the standard BCA method and 
all samples were adjusted to have the same total protein concentration. IGF-I Receptor β 
Antibody (Cell Signaling #3027) was added to the lysate at 1:100 and immunoprecipitation 
was allowed to proceed overnight in the cold room under gentle nutation. The next day, 
Protein G Magnetic Beads slurry (New England Biolabs) was added to the sample and 
incubated for 1h in the cold room. After extensive washing, bound protein was released 
from the beads and analyzed with Western blot using the same protocol as described in 
Chapter III. 
 
Synthesis of SIRB homodimers 
Di(N-succinimidyl) glutarate was purchased from Sigma Aldrich. BS(PEG)5 and BS(PEG)9 
were purchased from Pierce. Each crosslinker was dissolved in DMSO to give a stock 
solution of 200mM, stored at -20°C for up to three months. SIRB peptides were synthesized 
as previously described, and at the end of synthesis the N-terminus was left as an 
unprotected primary amine.  
Self-dimerization was performed by mixing 30uL of 2mM SIRB (dissolved in Reaction Buffer 
directly from lyophilized powder prior to reaction) and 0.25uL of 1.7mM crosslinker (from 
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200mM DMSO stock), and mixed gently overnight. The reaction mixture was then analyzed 
on LC/MS and purified on HPLC under standard procedures. 
Reaction Buffer: 
20% acetonitrile in PBS 
pH-adjusted to pH7.5 by adding ~ 3uL 6N NaOH to a total volume of 10mL. 
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